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ABSTRACT
 
Nanoscience and nanotechnology have successfully created different 
nanomaterials, which are defined as materials with at least one dimension between 1-100 
nm.  This small size gives nanomaterials unique and novel properties compared with bulk 
material, such as a high surface area, specific mechanical, optical and magnetic properties.  
These novel properties have stimulated the interest of using nanoparticles in a wide range 
of consumer products and applications including biomedical, pharmaceutical and drug 
delivery.  Silver and iron oxide nanoparticles attracted more attention commercially due to 
their antibacterial and magnetic properties, respectively.  So, the overall objective of this 
dissertation was: 1) to examine the implication of well-characterized polyvinylpyrrolidone-
coated silver nanoparticles (PVP-AgNPs) on human peripheral blood mononuclear cells 
(PBMCs) at environmentally relevant concentrations, and 2) to investigate the application 
of iron oxide nanoparticles in fat removal using high-fat diet-fed mice.  
AgNPs biological behavior, such as bio-uptake and accumulation, may be affected 
by their novel properties and they might show different behavior than bulk material and 
free Ag ions.  There is discrepancy in the results as to whether Ag toxicity is caused by 
nanoparticulate or ions from NP dissolution.  In most nanotoxicology studies lack of NP 
characterization in the relevant exposure media biased the NP dose and toxicity outcome.  
This study aimed to use in house synthesized and well- characterized PVP-coated AgNPs 
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for investigation of their bio-uptake and toxicity in PBMCs.  Synthesis protocol was 
successful in generating spherical and monodisperse PVP-coated AgNPs.  PVP-AgNPs 
showed more stability in the cell exposure media and no aggregation was observed at any 
exposed concentrations.  AgNPs and silver nitrate (which was used as Ag ion control) 
indicated the same overall toxicity.  Although, after normalizing toxicity to the amount of 
Ag that was taken up by cells, AgNPs seemed to be more toxic to cells than Ag ions.  Our 
results emphasize the importance of sufficient characterization of nanoparticles in proper 
exposure media over the exposure time to have a better understanding of nanoparticle 
behavior and interaction in biological systems for evaluating risk assessment in human 
exposure.  
Iron oxide NPs which are frequently used in nanomedicine, have recently been 
investigated for oil removal purposes [1].  However, in vitro and in vivo studies on iron 
oxide NPs toxicity have revealed little consistency of result due to the usage of different 
NP characterizations and concentrations.  In this study we used PVP-coated iron oxide NPs 
(that were used successfully before for oil removal from aqueous solutions) to remove 
dietary fat from mice fed with a high-fat diet.  Our animal data demonstrated that oral 
exposure of PVP-coated iron oxide nanoparticles at concentrations up to 20 mg/kg mouse 
body weight did not cause any significant decrease in the body weight and fat percentage 
of high-fat diet-fed mice.  Although, iron uptake by liver cells and some effects on glucose 
metabolism in HNP treatment was detected compared to controls.  No increase in 
inflammatory markers were observed using high doses of nanoparticle treated mice 
compared with high-fat diet.  Further studies using different concentrations of NPs with 
modified surface coatings should be performed to validate our findings.  Given the 
vii 
increasing demand for obesity treatments, nanomedicine approaches, coupled with our 
results, may provide substantial contributions toward progress in this area.  
viii 
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 Nanoscience, nanotechnology and nanoparticles 
Nanoscience, which refers to the study and manipulation of structures with at least 
one dimension between 1-100 nm (according to definition of the European Union [2], the 
American Society for Testing Materials [3] and the Scientific Committee on Emerging and 
Newly-Identified Health Risks [4]), and nanotechnology which is a multidisciplinary field 
that refers to the application of nanoscale material in the products, have been created 
different types of nanomaterials (NMs).  The properties of these material, such as electrical, 
thermal, mechanical, magnetic and optical, change as their size shifts to the nanoscale and 
this stimulates the increasing interest in the NM [5].  For example gold will show higher 
reactive properties in the nanosized scale than bulk material [6] and the yellow color of 
bulk gold turns into red when it approaches nano size [6, 7].  The difference between bulk 
and nanosized properties is due to their high surface area over volume ratio that increases 
the number of atoms on the surface and increase in interacting faces [8, 9] which lead to 
surface reactivity [10, 11].  Changes in surface reactivity and crystalline structure may 
influence NM behavior such as increase in toxicity as it is shown that titanium dioxide and 
aluminum oxide NPs have more toxic effects than the bulk material [12].   
1.1 NM synthesis methods 
Different methods are used for synthesizing nanomaterials and fabricating 
nanostructures.  These methods can be grouped into two categories: 1) top-down approach 
(physical method) and the 2) bottom-up approach (chemical methods) [13-15].  Top-down 
method begins from bulk material and then reduces to nanoscale using high-pressure 
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homogenization or milling [16].  In contrast, the bottom-up approach starts NMs from 
atoms and molecules and builds up to nanostructures through nucleation. 
1.2 NP classification 
Nanoparticles (NPs) can be classified into different classes based on their origin, 
shape or size.  Based on origin of NPs, they can be grouped as 1) naturally occurring NPs, 
2) incidental NPs, and 3) manufactured or engineered NPs [17-19].  Natural NPs are 
generated by natural processes and offers a wide range of small particles from inorganic 
ash and mineral particles found in the air, to selenium and sulfur NPs that are produced by 
yeast and bacteria [20].  Some natural NPs such as iron oxide NPs produced from wind-
blow mineral dust, serves as a micronutrient for phytoplankton which controls the CO2 
levels in the aquatic environment [21].  Incidental NPs are produced unintentionally as a 
byproduct of some other activities such as combustion processes.  For example, platinum 
and rhodium NPs released from automotive catalytic converters (which driving speed and 
traffic could control the releasing level of these NPs) [22].  Manufactured or Engineered 
NPs (ENPs) are produced for specific purposes by humans to serve as an ingredient in 
some products.  ENPs may be produced in different and particular shapes and compositions 
for different purposes such as in science, technology, medicine and industry.  ENPs are 
produced with different capping agents to make them more persistent in the environment 
(media) and they are made in definitive sizes and shapes to achieve their unique 
physicochemical properties.  These factors can affect the risk associated with ENPs and 
they can be more toxic than natural occurring NPs.  Therefore, it is reasonable that ENPs 
become the main focus of current research [17, 23, 24].  
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1.3 NM exposure 
The novel properties of NMs have accelerated the production and utilization of NPs 
in many consumer products.  Human may be exposed to engineered NMs through 
occupational, environmental and consumer exposure based on The Royal Society/ Royal 
Academy of Engineering report (2004).  Being exposed to occupational exposure is 
probable at all phases of a NMs’ life cycle.  NM exposure could occur while experimental 
procedures are happening to develop new materials (under laboratory conditions) which 
could cause incidental spills of materials.  In the final product, exposure may take place 
during packaging, transport or storage and finally, exposure may happen while NM product 
is being disposed of (at the end of product lifetime).  In many of these products, exposure 
can happen deliberate (usually by ingestion or dermal application) or incidental (including 
inhalation).  So, for every NM there is different routes of exposure depending on the 
production, use, and clearance.     
1.4 AgNPs application 
In the Nanodatabase (http://nanodb.dk/) as of 2018, more than 1100 consumer 
products containing NPs are listed which there are 379 reported products including AgNPs 
(35%) and making AgNPs the most commercialized NP in the market.  Because of high 
electrical and thermal conductivity [25-27], as well as their chemical stability and catalytic 
activity of Ag, they are valuable in microelectronics and medical imaging [28].  In addition, 
AgNPs show a broad spectrum of antibacterial and antiviral activity [29-32].  
Antimicrobial properties of AgNPs make them extremely popular in different consumer 
products such as soaps, plastics, food packaging, cleaning products, antibacterial wound 
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dressings, cosmetics, personal care products and textiles [25, 29, 33-39].  Ag containing 
textiles are popular for their antibacterial effect and their ability to reduce sweating odor 
[40].  AgNPs are also used as coating for medical products [41, 42] such as urinary 
catheters [43], scalpels and needles [44]. 
1.5.1 Human exposure to AgNP  
This rapid increase in AgNP usage in consumer products raises concern about its 
consequent adverse effect on environment and human health [17].  Ingestion, injection, 
inhalation, dermal and ocular contacts are possible routs of human exposure to AgNPs 
(Figure 1.1). A high dose of Ag may lead to argyria which is associated with the irreversible 
deposition of Ag in the skin [45].  Stammberger reported that application of Ag-containing 
nose spray for a year led to argyria [46] also in a clinical case it was reported that argyria 
happened after taking Ag-containing food supplements for a few months [47].   The World 
Health Organization (WHO) offers a 10 g Ag over the lifetime of human as a no observed 
adverse effect level (NOAEL), which matches to 0.1 mg L-1 Ag concentration in tap water 
(Guidelines for drinking water qualities, 1996).  However, the allowed tap water Ag 
concentration in Germany is 0.01 mg Ag L-1 (Trinkwasserverordnung). 
1.5.2 AgNP transformations  
AgNPs are very reactive (due to their high surface area and surface energy) and are 
susceptible to dynamically transform in biological media.  These transformations could 
change the behavior of NPs such as dissolution, aggregation and sulfidation and complicate 
the evaluation of risk associated to NP exposure [22].  To have a better evaluation of NP 
bioavailability, bio-uptake and toxicity, we should have an understanding about the type 
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and magnitude of NP transformations [22].  Surface interactions of NPs with biological 
components (such as proteins) will affect their physicochemical properties (size, shape, 
concentration and surface charge).  In case of proteins, formation of a protein corona on 
the surface of NPs decreases the reactive oxygen production and reduces the toxic effect 
[48].  Aggregation and dissolution are two key NP transformation processes which 
determine NP toxicity and bioavailability [17, 49].  Considering all this factors, 
comprehensive characterization of NPs in nanotoxicology studies is essential for pristine 
NPs, during exposure and after exposure in the proper exposure media.     
1.5.3 AgNP vs. Ag ion toxicity 
Toxicity of both NPs and ions in metal-based NPs has been investigated and relative 
role of these two has not been fully explained.  Depending on dissolved (ion) or particulate 
uptake, bioaccumulation and toxicity will be different as Baek et al., (2011) reported higher 
toxicity of copper and nickel oxide NPs than ions in bacteria [50].  In some NPs such as 
zinc oxide, dissolution alone could explain toxicity effects [51].  However, in NPs such as 
ceria and titanium that are determined as poorly soluble NPs, dissolution is playing the 
minimal role in toxicity [52, 53].  AgNP is considered as partially soluble NP for 
nanotoxicology purposes and many studies have been performed to investigate NP vs ion 
bio-uptake and toxicity [54, 55].  However, current methods for investigating the 
contribution of particles and ions in toxicity (uptake and accumulation) are relatively 
unreliable and require more development.  Some studies suggest that toxicity can be mostly 
explained by dissolved Ag from NP dissolution [56], whereas other studies indicate that 
the residual effect of NPs is contributing to toxicity along with ions [57, 58].   
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1.5.4 Core-shell NPs   
To overcome the uncertainty in identifying NP and ion role, bimetallic and 
isotopically labeled NPs have been recently used to measure bio-uptake and accumulation 
of metals in organisms [59-61].  Bimetallic NPs become very popular because of their 
fascinating sensing, electronic and optical properties [62] and higher functionality by 
combining multiple NMs which each holding unique advantage.  The properties can be 
modified by changing either the creating materials or the core to shell ratio.  The coating 
of the core NPs has different reasons such as surface modification, stability, dispersibility 
and controlled release of the core material [63].  Bimetallic NPs can have different forms 
such as alloy, nanowire and core-shell [64].  Between these types, bimetallic gold (Au) and 
Ag core-shell NPs have attracted more attention [65].  Outer Ag shell protects Au core 
from interacting with the media, therefore Au will be protected from dissolution and can 
be used as an internal standard, and Ag and Au ratios can be used to explain the Ag 
transformations (such as dissolution) in the media [66].  Physiochemical properties of 
bimetallic core-shell NPs uniquely depend on the composition of NP and thickness of core 
and shell that is determined by their end use and application [67].  Isotopically labeled NPs 
provided enhanced sensitivity to evaluate the rate of particles delivery to organism [68-72].  
Isotopically labeled NPs enhance the signal to noise ratio of the enriched isotope against 
the background (non-enriched isotope).  This property of NPs significantly decrease the 
detection limits within organisms by at least two fold [61].  In bio-uptake and 
bioaccumulation studies, isotopically labeled core-shell NPs allow the direct calculation of 
ion and NP uptake, since the core always remains as a particle, while the shell partially 
dissolves. 
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1.5.5 AgNP toxicity on human   
Cell toxicity induced by AgNPs has been studied in cells in vitro and in a wide 
range of organisms including bacteria, algae, nematodes, fish and mice [23, 25, 73-80].  It 
has been shown previously that injected AgNPs are translocated to the circulatory system 
and accumulate in the main organs (especially kidney, liver and spleen) [81].   Takenaka 
et al., reported that AgNPs can move into blood circulation system through blood 
pulmonary barrier and indicate a systemic distribution [82].  After entering the blood, NPs 
come in direct contact with peripheral blood mononuclear cells (PBMCs) that is consists 
of  mostly monocytes and lymphocytes (B and T cells) which are involved in cellular host 
defense system [83].  A few studies have been done to assess Ag uptake and toxicity on 
human blood cells [84-86], but they did not consider NP characterization and 
transformations in the exposure media that could alter NP toxicity.  
1.5 Engineered iron oxide NPs 
Engineered magnetic iron oxide NPs have been intensively established due to their 
biomedical and in vivo applications such as contrast agents in magnetic resonance imaging 
(MRI), targeted delivery of drugs and genes, cell separation, tissue repair and detoxification 
[87-95],  (because of their inherent low toxicity and magnetism property).   
The most common used techniques for iron oxide NPs synthesis include: thermal 
decomposition, hydrothermal reactions [96], micro-emulsion [97] and co-precipitation 
method [98].  Among these synthesis techniques, co-precipitation in aqueous solution is 
most widely used to synthesize superparamagnetic iron oxide NPs [99, 100] since it is more 
environmentally sustainable (needs low-toxicity organic solvent or does not need that).  
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Because of the colloidal nature of iron oxide NPs, their synthesis is a complex process.  
Almost all biomedical applications of iron oxide NPs require high magnetization value, a 
size smaller than 100 nm and a narrow size distribution [101].  Therefore, defining 
experimental conditions leading to a monodisperse NP and a reproducible process are the 
challenges in the synthesis process.  
1.6.1 Iron oxide NP toxicity  
Although the potential advantage of iron oxide NPs for therapeutic purposes is 
considerable, still there are some concerns about their potential toxicity and cellular 
damage on human associated with these particles.  The same nanoscale properties such as 
large surface area, increased surface reactivity, increase tendency to diffuse across 
biological membranes (because of nano-size) can potentially enhance their cytotoxicity 
[10, 102, 103].  Different studies demonstrated that iron oxide NPs are safe and non-toxic 
at concentrations below 100 µg L-1 [104, 105].  Alabresm et al. measured acute toxicity of 
PVP-coated iron oxide NPs on copepod and they did not observe any toxicity up to 25 mg 
L-1 NP concentration [106].  In most cytotoxicity tests on human and murine cell lines, iron 
oxide NPs did not show toxic effects up to 100 µg L-1 exposure concentration and toxicity 
was dependent on cell type and duration of exposure [107-110].   
1.6.2 Obesity 
Obesity is a widespread disease/syndrome in the modern world. It can noticeably 
reduce the quality of life and competes with smoking as the most common cause of 
premature death [111].  The rate of obesity including childhood and adolescent obesity has 
increased during the past decade and nearly 40% of U.S. adults have obesity [112].  Diet 
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composition, excess calorie intake, genetics, decrease in exercise and the built environment 
are risk factors that cause obesity and associated co-morbidity [113, 114].  Obesity is 
associated with more than 40 diseases and some health complications such as coronary 
heart disease, hypertension, stroke, type 2 diabetes and at least 13 different types of cancer 
[112, 115, 116].  The health care costs for obesity now is a major concern across developed 
countries.  According to CDC, the medical costs of obesity in the U.S. are estimated as 
$147 billion annually [112] and research suggests that individuals with obesity have 42% 
higher health care costs than normal weight people [112].  There are different weight-loss 
strategies including dietary modification, behavior modification, exercise, medication and 
surgery.  Some of the weight-loss drugs that are approved by U.S. Food and Drug 
Administrative (FDA) for treating obesity include: Orlistat (Xenical), Phentermine and 
Sibutramine (Meridia).  Medications are used as part of morbid obesity treatment, but they 
also can have serious side effects and have failed to provide an effective solution.  Currently 
there is no non-surgical method to achieve major weight loss and maintain that [111].  
Bariatric surgery includes the procedure of sleeve gastrectomy, biliopancreatic bypass, 
gastric banding, and gastric bypass.  Surgical options have their strengths and weaknesses 
as well such as perioperative mortality, early adverse event and late adverse event.  
1.6.3 Iron oxide NPs application  
With nanotechnology development, novel solutions for environmental remediation 
are emerging. For example, particles are used for cleaning of contaminated sites [117, 118].  
In this way manufactured magnetic iron oxide NPs are remarkable for oil remediation 
because of their magnetic property, low toxicity and low cost [119, 120].  Oil removal 
efficiency of iron oxide NPs has been studied before, and results showed 100% oil removal 
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in ultra-pure water, synthetic freshwaters and seawater [1].  With this introduction, we 
aimed to investigate the potential ability of iron oxide NPs to remove dietary fat in vivo 
using a high-fat-diet mouse model.   
1.6 Dissertation overview 
In short, the production and consumption of NMs in many consumer products have 
been accelerated due to the novel properties and advanced synthesis method of NMs.  This 
rapid increase in the commercialization of NPs raises concern about their safety and their 
potential toxic effect on human health.  Therefore, the overall aim of this dissertation is to 
investigate the implication and applications of silver and Iron Oxide NPs on Mammals. 
This dissertation is organized as follows: 
Chapter 2 investigates the uptake and toxicity of PVP-AgNPs and Ag ions (as control) 
to human PBMCs in physiologically relevant concentrations.  It provides characterization 
data of synthesized AgNP in exposure media and during exposure time, as well as the 
uptake and toxicity of AgNPs and Ag ions in PBMCs. 
Chapter 3 describes the efficiency of a facile and cost-effective synthesized PVP-coated 
iron oxide NPs to remove dietary fat and decrease body weight in a high-fat diet-fed mice 
compared with controls (LFD and HFD).  It provides results of changes in body weight, 
food intake and body composition of mice after 16 weeks of treatment, as well as iron 
accumulation in feces and tissues and hepatic inflammatory markers (TNF-α and MCP-1).  
Chapter 4 discusses and summarizes findings of this dissertation. 
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Figure 1.1 Routes of human exposure to Ag. The extensive use of nanosilver in consumer 
products introduces multiple ways for human exposure. (Adapted from Wen et al., 2016). 
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CHAPTER 2 
 
UPTAKE AND TOXICITY OF SILVER NANOPARTICLES AND 
SILVER IONS TO HUMAN PERIPHERAL BLOOD MONONUCLEAR 
CELLS 
14 
2.1 ABSTRACT 
Silver nanoparticles (AgNPs) are widely used in medical applications due to their 
antibacterial and antiviral properties.  Despite the increasing study of AgNPs, their toxicity 
and their effect on human health is poorly understood.  This is largely a result of such issues 
as poor control of NP properties as well as a lack of proper characterization and inadequate 
quantified bioaccumulation.  The aim of this study is to investigate the uptake and toxicity 
of well-characterized PVP-coated AgNPs on primary human cells (peripheral blood 
mononuclear cells) at physiologically relevant concentrations (10 - 1000 µg L-1).  AgNPs 
were synthesized in-house and characterized using a multi-method approach.  Results 
indicated relatively stable NPs in RPMI media with a decrease in size and greater 
polydispersity after 24 hours of exposure.  No aggregation of NPs was observed in the 
STEM images in the RPMI media during exposure time (24 hours).  A dose-dependent 
relationship between uptake and Ag concentration was detected for both AgNP and AgNO3 
treatment. In 1000 µg L-1 AgNO3 exposure, up to 11 ng Ag was detected in 2.5× 10
5 cells, 
which is about 2-fold higher than 500 µg L-1 exposure.  There was almost 2-fold increase 
in the Ag uptake into the cells in the AgNO3 treatment than NPs.  However, LDH assay 
did not show any significant difference in cytotoxicity of AgNPs and Ag ions. 
 
2.2 INTRODUCTION 
Nanotechnology is a rapidly growing industry that creates nanoscale products with 
novel physio-chemical properties [121].  Nanoparticles (NPs) are particles with at least one 
dimension between 1-100nm, which gives them unique properties and innovative 
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applications [122].  These particles are used widely in industry (oil remediation) [123], 
numerous commercial products such as cosmetics, electronics, and textiles, and in different 
biomedical and drug-delivery applications including the treatment of diseases [17, 124, 
125].  Silver nanoparticles (AgNPs) are one of the most commercialized NPs on the market 
and are widely used in medical products such as ointments, bandages and wound dressings 
[126-128] due to their antibacterial and antiviral properties [29, 30].  In fact, the use of 
AgNP in commercially-available products is anticipated to double in the next five years 
[129].  AgNPs have the potential to prevent bacterial colonization on different surfaces, 
such as catheters and prostheses [130, 131], which raises concern about Ag release in the 
body and their possible negative effects on human health.  For instance, the silver 
concentration in the blood of people without any occupational or medicinal exposure is 
<1µg L-1 [132].  However, in burn patients who are treated with silver containing 
antibacterial creams, Ag concentration in the blood can be found up to a concentration of 
310 µg L-1 [132].  Additionally, AgNPs that are used in food-related products might alter 
gut microbiota and modulate the systemic homeostasis of the intestinal tract [133, 134].  
A human body might be exposed to AgNPs through injection, ingestion, inhalation, 
and dermal and ocular contact [36].  As soon as AgNPs enter the body, they are translocated 
to the circulatory system and can come in direct contact with human peripheral blood 
mononuclear cells (PBMCs) before ultimately being distributed to the main organs where 
they accumulate [81].  PBMCs consist of monocytes and lymphocytes (B and T cells) and 
are responsible for the cellular host defense against foreign substances [83].  These cells 
secrete different inflammatory mediators after activation, including pro- and anti-
inflammatory cytokines.  Despite the increased usage and likely increased exposure of 
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AgNPs, there is a lack of quantitative analysis of bio-uptake and potential cytotoxicity of 
PBMCs after exposure to well-characterized AgNPs.  Different studies have investigated 
the bioavailability and cytotoxicity of AgNPs using different cell lines and rodent models 
[126, 135-137].  However, these immortalized cell lines are more resistant to toxicity 
effects that may be induced by AgNPs [138].  Furthermore, there are only a few studies on 
the bio-uptake and exposure of AgNPs on human PBMCs [84-86, 139-143].  Few, if any, 
of these studies investigate procurement, characterization and bio-uptake of NPs, 
transformations in exposure media, or use proper controls at relevant exposure 
concentrations.  
In the present study, we initially decided to synthesize and use isotopically labeled 
core-shell NPs to be able to directly calculate ion and particulate uptake and toxicity in the 
PBMCs.  Considering that, in the core-shell NPs core remains as particulate, while the 
outer shell dissolves partially.  We have synthesized unlabeled core-shell 
silver@gold@silver (Ag@Au@Ag) NPs following the method described by Merrifield et 
al. [144].  As synthesis of core-shell NPs is a more complex process than single NPs and it 
needs more alloted time and cost than single material NPs, we decided to optimize 
experiments using PVP-coated AgNPs, before moving to core-shell NPs.   
The overall aim of this study was to investigate the bio-uptake and toxicity of well-
characterized PVP-coated AgNPs on PBMCs at physiologically relevant concentrations. 
The specific objectives include; 
1) Investigate if cell culture media (RPMI) and exposure condition are capable of 
transforming PVP-coated AgNPs. We hypothesized that PVP-AgNPs shows 
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more stability in the media.  We investigated this through experiments 
measuring dissolution and aggregation of AgNPs during exposure time in the 
cell culture media. 
2) Quantify the uptake of Ag by human PBMCs in RPMI.  We hypothesized that 
uptake is faciliated by ionic Ag resulting from NP dissolution.  To test this, we 
exposed PBMCs to PVP-AgNPs and AgNO3 and measured Ag concentrations 
within cells over the exposure time. 
3) Investigate and compare toxicity of Ag in the form of NP and ion exposed to 
human PBMCs.  We hypothesized that Ag in the form of ion is more toxic to 
cells than AgNP.  To test this hypothesis, we assessed cell viability and cell 
metabolic activity in PBMCs.  
Comprehensive characterization of NPs plays a critical role in order to have a better 
eastimation of hazards and risks associated to the nanomaterials.  The goal of this study is 
to emphasize the importance of NP characterization in nanotoxicology studies to avoid 
over- or under- estimation of NP hazard assessment. 
 
2.3 MATERIALS AND METHODS 
2.3.1 Core-shell Ag@Au@Ag nanoparticle synthesis 
The tri-layered core@shell@shell NPs (Ag@Au@Ag) with both unlabeled Ag as 
the core and outer layer and isotopically labeled Ag107 as core and Ag109 as outer shell 
(Ag107@Au@Ag109) were synthesized following Merrifield and Lead 2016 protocol 
[144].  This synthesis includes four methodological steps as follows: 1) AgNO3 synthesis; 
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2) AgNP seed production and wash; 3) Adding Au layer (gold capping); and 4) outer Ag 
layer (silver capping).  The Ag metal powder (Ag107, Ag109, or unlabeled Ag) was 
converted to AgNO3 by boiling powder in HNO3.  A 50 mg of Ag powder was weight 
graph metrically into a plastic boat and then washed out completely into the mortar using 
10 mL of concentrated HNO3 (trace metal grade).  The suspension was pipette up and down 
and mixed until Ag is fully dissolved. The mortar was placed on the hot plate with a watch 
glass as a cap inside the fume hood and temperature was adjusted to 120°C.  The mortar 
was checked every 20-30 minutes and was swirled to avoid AgNO3 crystals from drying 
and burning.  Heat was removed once all acid was evaporated and only white crystals of 
AgNO3 was remained in the mortar.  All the AgNO3 powder was scrapped from the mortar 
and was collected into a dark, acid washed, scintillation vial for later AgNP production. 
Ag seed NPs (for both labeled and unlabeled Ag) were synthesized using a standard 
sodium borohydride reduction process following Romer et al., 2013 [145].  UHPW (400 
mL) was gravimetrically dispensed into a conical flask.  The flask was placed on the 200°C 
set hot plate while vigorously stirred to boil.  Proper amounts of AgNO3, silver citrate and 
NaBH4 solutions were prepared and NaBH4 stock was diluted 10-fold.  Once UHPW was 
boiling AgNO3 and silver citrate were added simultaneously and allowed to stir for a few 
seconds.  Then 0.5 mL of diluted NaBH4 was added dropwise (~ drop per 10 seconds).  As 
soon as NaBH4 was added, solution turned yellow.  The solution was heated for a further 
30 minutes, and then heat was turned off and solution was allowed to cool to room 
temperature.  Synthesized batch was placed in dark place overnight.  After synthesis 
AgNPs were washed by ultrafiltration using a diafiltration technique to avoid drying and 
NP aggregation as well as to remove any excess and unreacted AgNO3 or NaBH4 from 
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solution.  Millipore ultracel 3 kDa ultrafiltration disc was placed in the base of a plastic 
petri dish and was thoroughly rinsed three times with UPW and then was completely soak 
in UPW for 30 minutes.  Ultrafiltration device was set up and 200 mL of AgNP stock was 
transferred to the pressure filtration apparatus.  AgNPs were washed using nitrogen gas 
(100 psi).  When half of the total volume of AgNP batch was filtered, 100 mL of citrate 
solution was added to make the original volume.  The citrate solution was used to reduce 
NP growth or aggregation due to loss of surface citrate [146].  Washing process was 
repeated at least three times.  AgNPs are light sensitive and in all the procedures they were 
protected from light.  
A gold (III) chloride solution was prepared and was protected from light by 
wrapping in aluminum foil.  A 50 mL of citrate washed AgNP seed solution was placed on 
hot plate and heated to 60°C while moderately stirring using a magnet.  One drop of gold 
chloride solution was added to the heated AgNP seed in a 30 seconds time interval.  After 
each 5 minutes of adding Au, 1 mL aliquot of sample was taken and measured by the UV-
Vis until spectra peak showed a peak around 470 nm wavelength.  At this point heat was 
stopped and Ag@Au solution cooled to room temperature while stirring.  After adding Au 
cap color of solution changed from yellow to peach-red.  Washing process was repeated as 
explained in the AgNP seed section. 
Ag@Au NPs were heated to 100°C while stirring and solutions of AgNO3 and 
citrate were prepared. One drop of each solution mentioned above was added to NP batch 
simultaneously and dropwise.  After adding each drop and 5 minutes of stirring 1 mL 
aliquot of sample was taken and measured by UV-Vis to monitor the growth of Ag outer 
layer.  After the surface plasmon resonance reached 410 nm heat was removed and 
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Ag@Au@Ag solution was stirred to cool to room temperature and was washed the same 
way as explained above. 
2.3.1 Synthesis and characteriozation of PVP-AgNPs 
Citrate-capped AgNPs (cit-AgNPs) were synthesized by the standard reduction of 
silver nitrate (AgNO3) in trisodium citrate as described in previous publications [145, 147, 
148].  Briefly, separate solutions of AgNO3, trisodium citrate, and the reducing agent 
sodium borohydride (NaBH4) were prepared.  AgNO3 and trisodium citrate were mixed 
together while stirring vigorously and NaBH4 was added in a dropwise fashion.  The 
solution was heated slowly to boiling, heated for a further 90 minutes, and then left 
overnight to cool in the dark.  After synthesis, the NPs were washed by ultrafiltration (3 
kDa cellulose membrane EMD Millipore) using a diafiltration technique to avoid drying 
and NP aggregation as well as to remove any excess and unreacted AgNO3 ions or NaBH4.  
The washing process was repeated at least three times and after each wash the trisodium 
citrate solution was added to make the original volume.  A citrate solution was used to 
reduce NP growth/aggregation due to re-equilibration and loss of surface citrate [146].  The 
final reactant concentrations were < 1% of the original.  Cit-AgNPs were then recapped 
with polyvinylpyrrolidone (PVP) using the ligand exchange approach [147, 149].  A 
solution of PVP10 (Mw 10000, sigma Aldrich) was added to the NP batch while stirring 
vigorously for one hour.  PVP is a non-toxic polymer [150, 151] used to sterically stabilize 
particles by strongly binding to the AgNP core [147, 148] and protect them from 
dissolution and aggregation in complex media [149, 152].  
Z-average hydrodynamic diameter and polydispersity index (PDI) of PVP coated 
AgNPs (PVP-AgNPs) were measured using dynamic light scattering (DLS) with a Malvern 
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Zetasizer NanoZS (Malvern Instruments, MA, USA).  The colloidal stability (zeta 
potential) of PVP-AgNPs was measured by laser Doppler electrophoresis (Malvern 
Zetasizer NanoZS, MA, USA).  The mean of at least three consecutive measurements was 
reported.  Absorption spectra of PVP-AgNPs was recorded in triplicate over the 
wavelength range of 200-800 nm using a UV-Vis spectrometer (UV-2600, Shimadzu Co., 
Kyoto, Japan).  Transmission electron microscope (TEM) and scanning transmission 
electron microscope (STEM) samples were prepared using an ultracentrifugation-based 
method in UHPW and RPMI media, respectively.  Briefly, a carbon coated copper grid 
(300 mesh; Agar scientific) was placed into a clear plastic centrifuge tube and 4 mL of 
sample was added into the tube very slowly.  The tube was covered by parafilm and was 
centrifuged using vacuum centrifugation for 1 hour at 50,000 rpm.  The grid was rinsed 
thoroughly with high-purity water and left overnight to fully dry.  The grids were then 
imaged by a Hitachi HT8700 and HD2000.  The PVP-AgNP batch was checked for purity 
using Energy-dispersive X-ray spectrometry.  The final concentration of the PVP-AgNP 
batch was measured using inductively coupled plasma optical emission spectrometry (ICP-
OES; Varian 710-ES).  PVP-AgNP characterization in media without cells was conducted 
using UV-Vis spectrometer and STEM.  Dissolution rate was measured at relevant 
exposure concentrations of PVP-AgNPs and at 0 and 24-hour time points using ICP-MS 
(inductively coupled plasma mass spectrometry- NexION 350D, Perkin Elmer Inc., 
Massachusetts, USA).  
2.3.2 Measurement of the concentration of total, dissolved, and NP fraction 
When exposed to oxygen, AgNPs oxidize through oxidative dissolution 
mechanisms and Ag ions will be released from the surface of AgNPs to the solution [84, 
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153].  To determine the extent of ionic silver release from PVP-AgNPs in media (without 
cells), we used a centrifugal ultrafiltration method.  Aliquots of samples were taken at 0 
and 24-hour time points and were subsequently added to the top of centrifugal 
ultrafiltration tubes (Pall Corporation, Microsep Advance with 3kDa omega; maximum 
volume 4 mL) and centrifuged at 4000 rpm for 20 minutes at 20°C (Eppendorf 5810R 
centrifuge) [154, 155].  The original (total Ag) and ultrafiltered (dissolved Ag) samples 
were then acidified with concentrated nitric acid (70% HNO3) and diluted to 1% acid prior 
to the measurement of Ag concentration with ICP-MS.  Each sample was measured in 
triplicate and Indium (In115) was used as an internal standard.  The detection limit was 
calculated as 0.024 µg Ag L-1.  The validity of analytical method was checked every 12 
measurements with 2 quality controls (Blank and 5 µg Ag L-1).  A serial dilution of Ag 
standard solution (1000 µg mL-1, VWR analytical, USA) was used for calibration curve.  
To measure and compare the loss of Ag (dissolved or PVP-AgNPs) on the ultrafilter 
membrane or sorption to the exposure tube, 500 and 1000 µg L-1 concentrations of Ag (as 
AgNO3) was prepared in UHPW and RPMI media.  Samples were collected at 0 and 24-
hour time points and were ultrafiltered and measured by ICP-MS in triplicate as previously 
described and were used to correct samples results. 
2.3.3 Isolation and culture of peripheral blood mononuclear cells (PBMCs) 
Human blood for 6 individual people was purchased from the New York Blood 
Bank (New York City, NY) and PBMCs were isolated by gradient centrifugation using 
Ficoll-paque Plus (GE Healthcare Bio-Sciences AB, Sweden).  In brief, peripheral blood 
from healthy volunteers was diluted with an equal volume of sterile phosphate buffer saline 
(PBS; Gibco by life Technologies) and slowly layered onto the Ficoll-paque media 
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solution.  Tubes were centrifuged at 500 g for 30 to 40 minutes at 18°C.  After 
centrifugation a thin layer of mononuclear cells could be detected between plasma and 
Ficoll-paque media.  The layer of mononuclear cells was transferred to a sterile tube and 
was washed with sterile PBS three times.  After the last wash, cells were resuspended in 
RPMI1640 media (Sigma- Aldrich, Taufkirchen, Germany), supplemented with 10% fetal 
bovine serum (FBS; Gibco by Life Technologies) and 100 IU/mL pen/strep (Gibco by Life 
Technologies) and counted using trypan blue. The isolated cells were adjusted to 2.5×105 
in 24 well-plate (Costar, ME, USA) for cell culture and bio-uptake experiments, and 
2.5×104 cells in 96 well-plate (Corning Incorporated, NY, USA) for cell viability and 
metabolic activity test.  
2.3.4 Uptake of Ag into PBMCs and mass balance 
ICP-MS was used to quantify the uptake of Ag in PBMCs after exposure to PVP-
AgNPs and AgNO3 (as control).  Freshly isolated PBMCs were seeded in 24-well cell 
culture plates at a density of 2.5×105 cells.  PVP-AgNP and AgNO3 stock (25 mg L
-1) were 
diluted with cell-culture water (Sigma-Aldrich, Taufkirchen, Germany) and added to attain 
final concentrations of 10, 100, 500, and 1000 µg L-1 prior to exposure.  The AgNP solution 
was sonicated for 20 minutes to reduce NP agglomeration immediately before exposure.  
The plates were then incubated for 24 hours at 37°C and 5% CO2.  Each exposure study 
was run in triplicate.  After 24 hours each well was collected, and the cells and supernatant 
were separated using a centrifuge (10 min x 300g).  The supernatant was used for Ag 
analysis to determine the amount of Ag that was not taken up by PBMCs.  Cells were 
washed three times with PBS using a centrifuge (15 min x 300g) and then lysed and 
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digested with concentrated HNO3.  The Ag ion or AgNP uptake by cells was measured by 
quantifying the total Ag concentration in the digested samples using ICP-MS.  
2.3.5 Measurements of viability and metabolic activity of cells  
To investigate cytotoxicity of Ag on PBMCs we used two different assays that 
measure cell damage (LDH) assay and metabolic activity (MTS) assay.  LDH is a 
colorimetric assay that measures the membrane integrity and quantitatively quantify lactate 
as a substrate that is released from lysed cells into the media as a biomarker.  LDH 
cytotoxicity assay (Dojindo laboratories, Kyoto, Japan) was performed according to 
manufacturer instructions.  In brief, immediately after isolation of PBMCs, cells were 
treated in the absence (control) and presence of increasing doses of PVP- AgNPs, AgNO3 
(as positive control), AgNO3 -PVP and PVP (10, 100, 500, and 1000 µg L
-1) in 96 well 
plates for 24 hours in 6 replicates.  Subsequently, 100µl of the assay buffer was added to 
each well and incubated at room temperature in the dark.  After 30 minutes, 50µl of the 
stop solution was added to each well and the LDH activity of the samples was assessed by 
measuring NADH absorbance at 490nm.  
Cell metabolic activity was measured using 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulphenyl)-2H-tetrazolium (MTS; Promega, Madison, WI) 
assay.  MTS assay measures the insoluble formazan that is accumulated in the 
metabolically active cells.  The MTS assay was performed according to the manufacturer’s 
protocol. Briefly, isolated PBMCs were exposed to 0, 10, 100, 500, and 1000 µg L-1 of 
PVP- AgNPs, AgNO3, AgNO3 -PVP and PVP in 96 well plates in 6 replicates for 24 hours.  
Subsequently, MTS dye was added to each well, and incubated at 37°C in a 5% CO2 
25 
humidified incubator for 4 additional hours.  The optical density of reduced MTS was 
measured at 490 nm using a 96-well plate reader spectrophotometer.  
The potential interference of particles with LDH and MTS assay was also examined 
in the cell free conditions and subtraction of background absorbance was applied where 
necessary. 
2.3.6 Statistical analysis  
Data for uptake, cell viability and metabolic activity are expressed as means ± 
standard errors (SEs) for six separate donors.  Statistical analyses were evaluated using the 
ANOVA with random effects to detect the significant differences between the treatment 
and control groups.  P-values with less than 0.05 were considered statistically significant. 
All analyzes were performed using SAS software (SAS 9.4). 
 
2.4 RESULTS 
2.4.1 Core-shell NP characterization 
Characterization of core-shell NPs in different synthesis steps are shown in Table 
2.2.  Characterization of core-shell NPs (Ag@Au@Ag) in water resulted in an absorption 
spectrum (measured by UV-Vis) that was indicative of Ag@Au@Ag NPs (407 nm), an 
average hydrodynamic size of 28.23 ± 9.3 nm and a polydispersity index (PDI) of 0.12 ± 
0.04.  Figure 2.1a and b shows the progression of the Ag wavelength to form Ag@Au and 
Ag@Au@Ag, respectively.    
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2.4.1 PVP-AgNP characterization 
In this study we used a multi-method approach to characterize pristine AgNPs 
including DLS, UV-Vis, TEM and ICP-MS.  DLS showed a Z-average hydrodynamic size 
of 33.7 ± 0.7 nm (mean ± standard deviation) and PDI as 0.18, indicating a reasonably 
monodisperse particle suspension (Table 2.3).  A representative curve is shown in Figure 
2.2a.  The zeta potential was measured as -10.3 ± 2.1 mV for PVP-AgNPs. UV-Vis spectra 
exhibited a characteristic absorption peak at 390 nm for Ag (Figure 2.2b).  A mean core 
size of 4.9 ± 0.3 nm was indicated by TEM imaging and confirmed a spherical shape of 
NPs (Figure 2.2c and d), which was proven to be pure silver by performing EDX analysis 
(Figure 2.2e).  The peaks of other elements (C, Cu, and O) in EDX analysis are due to grid 
material that was used for sample preparation.  DLS estimates the hydrodynamic size of 
NPs, which includes the hydration shell around NPs and should be the same as, or larger 
than the core size of NPs measured by TEM.  Characterization values for pristine PVP-
AgNP can be found in Table 2.3.  
STEM images of 1000 µg L-1 PVP-AgNPs in RPMI media at the time points of 0- 
and 24-hour exposure are shown in Figure 2.3.  STEM images showed a mean size of 29 
± 4.9 nm at the T=0 hour in RPMI (Figure 2.3a), which is larger than the size of pristine 
NPs measured by TEM in the UHPW (4.9 ± 0.3 nm, p < 0.05).  STEM images did not show 
any evidence of aggregation of NPs.  After 24 hours in exposure media, PVP-AgNPs 
remained spherical, with a mean size of 17 ± 11 nm (Figure 2.3c).  Figure 2.3b and d show 
a skewed distribution and greater polydispersity of PVP-AgNPs in the RPMI media after 
24 hours of exposure.  Extinction spectra of PVP-AgNPs at 100, 500 and 1000 µg L-1 
concentrations in exposure media during 24-hour time point are presented in Figure 2.4.  A 
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decrease in the UV-Vis absorbance was observed for all concentrations.  A small red shift 
and broadening in the Ag peak, especially in 1000 µg L-1 PVP-AgNP concentration was 
observed during 24-hour exposure.  Full width half maximum (FWHM) for both 500 and 
1000 µg L-1 exposure concentration increased (44 nm to 81 nm and 49 nm to 140 nm, for 
500 and 1000 µg L-1, respectively) after 24-hour exposure. 
2.4.2 Dissolved Ag measurement using ICP-MS 
Ag dissolution in the culture media was measured after addition of PVP-AgNPs at 
T=0 hour (sample collection was performed immediately after addition of AgNP) and T=24 
hour, which matches the total exposure time in the experiment using centrifugal 
ultrafiltration method.  For PVP-coated AgNPs, no dissolved Ag was measured in the 
filtrate during the exposure time (T=0 and 24 hours, Figure 2.5a).  The original Ag 
concentrations were found nearly unchanged under the experimental conditions (Figure 
2.5b).  The dissolution experiment was repeated at the same condition in the presence of 
AgNO3 as a control for Ag ions.  Figure 2.5c and d show that Ag concentration dropped 
from 60 µg L-1 to less than 0.5 µg L-1 for 500 µg Ag L-1 exposure, and from 600 µg Ag L-
1 to less than 4 µg L-1 for 1000 µg L-1 at T=0 hour.  After 24 hours of exposure, the Ag 
concentration dropped from 190 µg L-1 to 0.1 µg L-1 for the 500 µg L-1 concentration, and 
from 200 µg L-1 to 0.3 µg L-1 for the 1000 µg L-1.  To confirm the results in the media, and 
to compare the dissolution in media and UHPW, the dissolution test was repeated using 
AgNO3 in UHPW and media at two concentrations (500 and 1000 µg L
-1).  Results 
indicated whole recovery of total Ag in UHPW at both concentrations and Ag loss in media 
and in ultrafiltered samples.  A representative image for dissolved and total Ag 
measurement for AgNO3 in UHPW and media is shown in Figure 2.6.  
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2.4.3 Ag uptake to the cells and mass balance 
After 24 hours of exposure, the total Ag content that was considered internalized or 
strongly bound to the cells was measured using ICP-MS in the digested samples after three 
washes.  An increase in cellular binding and uptake of Ag in PBMCs was observed with 
increase in exposure concentration from 10 µg L-1 to 1000 µg L-1 for both PVP-AgNPs and 
AgNO3 treatments (Figure 2.7).  At concentrations of 500 and 1000 µg L
-1 more Ag was 
detected in the cells in the Ag ion treatment than AgNP (p < 0.05).  No significant 
difference in the uptake of Ag in PBMCs was detected in AgNP and AgNO3 treatments in 
the lower concentrations (10 and 100 µg L-1).  
Ag content was measured in the supernatant using ICP-MS and mass balance was 
calculated.  Mass balance results (Table 2.4) indicate that after 24-hour exposure at the 
1000 µg L-1 concentration the measured internalized Ag was 0.5% in PVP-AgNP and 1% 
in AgNO3 of total Ag in the treatments.  Furthermore, at the 1000 µg L
-1 concentration, 
42% and 16.6% of total Ag was detected in the supernatant as NP and ion, respectively.  
Figure 2.8 shows Ag content that is internalized or attached to cell surface of PBMCs in 
AgNPs and AgNO3 treatment in each of 6 individuals.  Mass balance data for each person 
for AgNP and AgNO3 treatments are presented in Table 2.5. 
The ratio of cell to supernatant uptake did not show any significant increase in PVP-
AgNP treatment as a result of the increase in dose.  However, in AgNO3 treatment this ratio 
increased in a dose-dependent response (Table 2.4).  
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2.4.4 Impact of PVP-AgNP and Ag ion on PBMC viability and metabolic 
activity 
Cell membrane integrity as a marker for cell viability was measured by LDH 
release.  PBMCs were exposed to PVP-AgNP, AgNO3, AgNO3-PVP and PVP at 
concentrations of 0 to 1000 µg L-1.  AgNO3 was used as a positive control and AgNO3-
PVP was used to examine possible interactions between Ag ions and PVP in cell toxicity.  
In PBMCs exposed to PVP, no significant increase in LDH release was detected at any 
concentration.  Both PVP-AgNPs and AgNO3 increased LDH release in a dose dependent 
manner compared to the control (without Ag), starting from 100 µg L-1 concentration 
(Figure 2.9a).  No significant effect was observed in 10 µg L-1 concentration.  Cell toxicity 
(LDH test) became significant from 10 µg L-1 for AgNO3-PVP and continually increased 
up to 500 µg L-1.  No significant difference was observed between PVP-AgNP and AgNO3 
(or AgNO3-PVP) treatments at any concentration. 
The effect of Ag on metabolic activity of PBMCs was measured by the MTS assay.  
Similar to the cell viability test, cells were exposed to different concentrations of PVP-
AgNP, AgNO3, AgNO3-PVP and PVP for 24 hours.  Metabolic activity of cells was 
elevated for all treatments at 10 and 100 µg L-1 compared to the control (0) (Figure 2.9b).  
PVP treatment did not cause any decrease in metabolic activity at any concentration.  A 
significant decrease in cell metabolic activity for PVP-AgNP, AgNO3, AgNO3-PVP, 
compared to the control group, started at 500 µg L-1 and continued at 1000 µg L-1.  At 1000 
µg L-1 Ag concentration, a significant difference was observed between AgNO3 and 
AgNO3-PVP with PVP-AgNP treatment.  The highest reduction in metabolic activity was 
found with AgNO3-PVP treatment, which elicited a 20% decrease in metabolic activity 
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compared to the control group.  Results for cell viability and metabolic activity of PBMCs 
for each person are presented in Figures 2.10 and 2.11, respectively.  
A Pearson correlation coefficient was calculated to assess the relationship between 
uptake and cytotoxicity (LDH assay) of PVP-AgNPs and AgNO3 (Figure 2.12).  A 
moderate but significant positive correlation was observed between uptake and toxicity of 
AgNPs (r = 0.56, p = 0.01).  With AgNO3 treatment, Person 5 displayed a different trend 
in cell viability and Pearson correlation; considering Person 5 in the correlation, uptake 
and cytotoxicity did not show significant relationship (r = 0.314, p = 0.2).  However, 
excluding Person 5 from analysis changed the correlation to a moderate but significant 
correlation between uptake and toxicity (r = 0.52, p = 0.04).  
 
2.5 DISCUSSION 
Because of antibacterial properties, AgNPs have been used in several consumer 
products and therapeutic purposes which increases the human exposure.  Most of the 
previous studies investigating uptake and toxicity of AgNPs on human PBMCs have failed 
to examine transformation of NPs during the exposure time in the exposure media and to 
use physiologically relevant Ag concentrations.  Therefore, the purpose of this study was 
to investigate the uptake and toxicity of well-characterized AgNPs on PBMCs at low 
concentrations. 
Physicochemical properties (such as small size, high surface area per mass and 
surface reactivity) of nanoparticles determine their interaction with biological systems 
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[156].  Inadequate characterization of nanoparticles may lead to over- or under- estimation 
of nanoparticle hazard assessment.  PVP-coated AgNPs were synthesized and 
characterized in UHPW and cell culture media (RPMI) containing 10% FBS before and 
after exposure time using a multi-method approach.  DLS results confirmed a 
monodisperse AgNP solution with a relatively narrow distribution.  STEM images 
indicated an increase in size when transitioning from water to media and a subsequent 
reduction after 24 hours in the RPMI.  In addition, the polydispersity showed an increase 
in the media.  The increase in size and polydispersity are likely related to (partial) 
dissolution of existing NPs and re-precipitation of existing NPs, AgNP ripening or forming 
new small NPs through nucleation. Subsequent reduction in size is explained by dissolution 
of AgNPs, through oxidation [153].  This interpretation is supported by UV-Vis spectra 
that shows a decrease in the absorbance of the Ag peak, a red shift and greater 
polydispersity.  Although not directly studied, dissolved silver chloride complexes and 
other particles were also likely formed [157].  There is no evidence that aggregation played 
a large role in NP transformations due to protection by the PVP, or possible protein 
interactions in the RPMI media [158, 159].  This result is in agreement with a previous 
study that found that aggregation of PVP-coated AgNPs was not observed in the hMSC 
cell culture media using focus ion beam (FIB) [160].  Furthermore, Kittler et. al. reported 
that media containing 10% FCS (fetal calf serum) will prevent PVP-AgNPs from 
agglomeration by either coating NPs or inducing ligand exchanging of PVP with proteins 
[161]. 
Dissolved oxygen in the solutions tend to oxidize AgNPs resulting in Ag ion release 
from the NP surface.  The Ag ion release kinetics depend on temperature, media 
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composition, size and surface functionalization of NPs [162].  It has been suggested that 
toxicity of Ag has been linked to Ag ion release and availability [159, 163, 164], whereas 
others have suggested a direct effect related to the AgNP [57].  As the exposure media 
(RPMI) is a complex culture media that contains different proteins and factors, it can alter 
the surface reactivity of NPs and change the possible mechanisms for uptake and toxicity.  
We measured the amount of Ag release during the exposure time in UHPW and RPMI 
media. We could not detect any Ag in the dissolved fraction of PVP-coated AgNPs.  
However, in the AgNO3 dissolution test in RPMI, 100% recovery of Ag in the dissolved 
fraction and total exposure was not obtained. The dissolved Ag measurement for AgNO3 
in RPMI suggests a very quick loss of Ag with the 500 µg L-1 Ag concentration.  After 24 
hours of exposure Ag come back into suspension to some extent (3 fold).  However, in the 
1000 µg L-1 Ag concentration, there is a continuous loss over exposure time.  These results 
suggest that some Ag ion is lost either by attaching to the container wall or during the 
filtration process due to forming larger complexes with biomolecules in the media or 
reprecipitation (or a mixture of both events) resulting  in the formation of an Ag complex 
with a molecular weight above the nominal value of the 3kDa filter membrane.  Since 
RPMI media contains chloride (in the form of potassium chloride and sodium chloride) 
that can lead to reprecipitation of Ag ions as silver chloride or precipitate within a protein 
and form an agglomeration of proteins [157].  Furthermore, cysteine and proteins 
containing a thiol group are found in FBS that have high affinity to Ag ions and NPs.  
Cysteine could form a complex with Ag ions in the RPMI and be removed from exposure 
whish is supported by previous works that cysteine was used to decrease Ag ion availability 
in the exposure media (acts like a strong Ag ion ligand) for determining AgNP and Ag ion 
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toxicity contribution [74, 165].  Dissolution results indicate that PVP-coated AgNPs are 
more consistent and stable in the exposure media, whereas dissolved Ag is much more 
prone to transformation. 
Though the exact mechanism of NP uptake into the cells is not fully understood, 
endocytosis has been mentioned as a possible mechanism [151, 166].  Previous studies 
have shown NP uptake into PBMCs using flow cytometry [84], electron microscopy [139] 
and combined FIB (focused ion beam milling)/SEM [160].  We used ICP-MS to quantify 
the total amount of Ag (internalized or strongly bound) in digested PBMCs after 24 hours 
of exposure to PVP-AgNPs and dissolved Ag.  For both AgNP and Ag-ion exposure, the 
amount of Ag that was taken up by cells increased as Ag concentration increased, which is 
consistent with previous literature [167].  There was a significant difference between Ag 
that was detected in the cells in AgNO3 treatment compared to NP at 500 and 1000 µg L
-1 
concentrations (Figure 4).  As it was shown in previous studies that a higher amount of Ag 
ion was measured in cells in comparison to those which were exposed to AgNPs at the 
same doses [168].  The higher uptake of Ag ions in the cells could be due to higher uptake 
rate for dissolved Ag than AgNP [169].  A limitation of our investigation is that we did not 
measure the amount of dissolved Ag in digested cells exposed to AgNPs which could be 
released due to dissolution of AgNPs.  This transformation of AgNPs to Ag ions may cause 
toxicity that is referred to as the Trojan-horse type mechanism (that AgNPs acts as a carrier 
for Ag ions) in the case that toxicity is attributed to Ag ions [170, 171]. 
It is important to point out that the type of cell and the kinetics of cellular uptake 
may also impact NP uptake [160].  Human PBMCs primarily consist of monocytes and 
lymphocytes (mostly T cells).  Monocytes are known for their phagocytic properties and 
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phagocytosis is suggested as one of possible mechanisms for Ag uptake by cells [126].  
The number of monocytes in the blood stream of different individuals could be elevated 
due to chronic inflammatory diseases or viral infection.  By using flow cytometry and 
FIB/SEM it has been shown that in PBMCs exposed to AgNPs and AgNO3, monocytes 
accumulate more Ag in the form of NP in the cytoplasm than T lymphocytes [84, 160].  
Therefore, the higher ratio of monocytes to lymphocytes could affect uptake of Ag in 
PBMCs. As Figure 2.8 shows different Ag uptake levels for each individual. 
Mass balance calculation results did not show any significant differences between 
Ag uptake in AgNP and AgNO3 treatment at 10 and 100 µg L
-1 Ag concentration.  
However, at 500 and 1000 µg L-1 the amount of Ag uptake in AgNO3 treatment was almost 
2 times higher than AgNP treatment [169].  For all treatments and concentrations, we could 
not get 100% recovery, and some Ag was lost during exposure and sample preparation (e.g. 
attached to exposure plate, pipet tips, centrifuge tubes and during cell washes).  
Cell to supernatant uptake percentages showed an increase in AgNO3 treatment 
with an increase in the exposure concentration.  Interestingly, in cell viability test (LDH 
assay) in 500 µg L-1 AgNP and AgNO3 treatment same cytotoxicity was detected.  
However, cell to supernatant ratio showed more than a 3-fold increase in AgNO3 treatment 
compare to AgNP. 
Toxicity may be affected by different parameters including particle size, surface 
area, incubation time, cell type, NP and cell concentration, growth condition and culture 
media.  In previous studies, different viability assays were used to measure cytotoxicity of 
AgNPs in human PBMCs [84-86, 139-143].  In this study we used LDH leakage assay for 
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measuring cell viability and MTS assay for cell metabolic activity measurement.  
Metabolic activity of cells showed an increase for all treatments at 10 and 100 µg L-1 
compared to the control, which is consistent with the results of Greulich et. al. who found 
an increase in cell activity at sub-lethal concentrations of AgNPs in hMSCs [159].  
Cytotoxicity of both PVP-AgNPs and AgNO3 was initiated from 100 µg L
-1 Ag 
concentration in LDH assay, as was reported by Orta-Garcia et. al.  They measured PBMCs 
viability using trypan blue exclusion assay and reported toxicity of AgNPs starting from 
100 µg L-1 [139].  LDH and MTS results are in agreement in PVP-AgNP, AgNO3, and 
AgNO3-PVP exposure at 500 µg L
-1, which means a decrease in the number of live cells 
leads to a decrease in metabolic activity.  Interestingly, in the100 µg L-1 exposure, more 
dead cells were detected in LDH while metabolic activity was increased.  This could be 
explained by the higher mitochondrial activity of live cells because of the treatments.  LDH 
results did not support MTS results at 1000 µg L-1 for AgNO3 and AgNO3-PVP treatments 
(results for LDH not presented).  This variation between LDH and MTS results possibly 
came from some artifacts that lead to a false negative outcome.  In the background test that 
was done for both LDH and MTS assay (without cells), an increase in the LDH absorbance 
of 1000 µg L-1 AgNO3 and AgNO3-PVP compared to the control (0) was detected, which 
indicates inactivation of LDH molecules by ions in the exposure media [172, 173]. 
In this study, we reported AgNP cytotoxicity started at low concentrations (100 µg 
L-1).  However, in some of the previous studies that MTT assay was used for measuring 
cell viability, any decrease in cell viability (metabolic activity) was not detected even at 
high concentrations of AgNPs.  There is evidence that Ag toxicity to cells occurs through 
oxidative stress by the generation of reactive oxygen species (ROS) which leads to the 
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release of pro-inflammatory cytokines and ultimately cause cell death [174, 175].  MTT 
assay measures mitochondrial activity and in the situation that elevated ROS is expected, 
mitochondrial activity will increase.  There could be different reasons that a decrease in 
MTT activity may not be seen even at high concentrations of AgNPs; 1) Using such a high 
NP concentration (1- 15 mg L-1) increases the possibility and rate of NP aggregation.  
Toxicity, reactivity, fate, transport and risk of NPs is related to aggregation. Large 
aggregated NPs tend to be deposited in the exposure media and therefore become less 
available to the cells.  2) Cytotoxicity of Ag could increase mitochondrial activity in live 
cells but still lead to some cell death.  In this case, there might be a smaller number of live 
cells that is not reflected in the mitochondrial activity.  Therefore, prudent interpretation 
and validation of LDH and MTS (MTT) results should be considered in nanotoxicology 
studies.  
Cell uptake was normalized against Ag concentration that was available to the cells 
in the exposure media for both AgNP and AgNO3.  Cell to supernatant ratio suggested that 
for the same added Ag mass, lower uptake was detected in the AgNPs treatment than 
AgNO3.  It suggests that as per unit mass of Ag that was taken up by cells, NPs showed 
more toxicity than Ag ions, or some other toxicity mechanisms that are involved in Ag 
cytotoxicity.  However, cell viability results show the same cytotoxicity for both AgNP 
and AgNO3.  The role of the epidermal growth factor receptor (EGFR) in toxicity of PM2.5 
and diesel exhaust particles  (DEP) was studied and an upregulation of EGFR ligand was 
confirmed in human airway epithelial cells [176, 177].  Unfried et al. suggested that EGF 
receptor activation by NPs may lead to different cellular outcomes such as apoptosis and 
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proliferation through the activation of the EGF receptor [178].  However, for engineered 
NPs, EGFR signaling needs to be investigated more.  
A moderate correlation between uptake and toxicity of AgNPs and AgNO3 was 
displayed using the Pearson correlation coefficient (excluding person 5 from calculations).  
Person 5 in the toxicity experiment showed a different trend compared to other samples.  It 
is not clear if this discrepancy was a result of variability between individuals or a result of 
experimental error.  
In summary, our study suggested that our complex exposure media (RPMI) could 
alter NP characterization and properties that is a precursor for assessing their toxicity and 
uptake.  Comprehensive characterization of NPs in toxicology studies is an important factor 
as there may or may not be a positive relationship between NPs and their potential toxic 
effect. 
 
2.6 LIMITATIONS 
There are some methodological limitations for this study including, but not limited 
to, a small sample size due to cost of sample collection and lack of time.  In addition, no 
information was provided by the blood bank regarding sex, race, specific sicknesses (that 
could affect the ratio of white blood cells), age, body mass index (BMI), diet or different 
ratio of cells in the blood (monocytes and lymphocytes) of donors.  
 
38 
 Table 2.1 List of chemicals used in NP synthesis. Chemicals used in core-shell 
(Ag@Au@Ag) and PVP-coated AgNPs synthesis. 
 
No. 
Chemical 
Name 
Chemical 
Structure 
MW 
(gramMol-1) 
Supplier 
1 Ag 107 Ag 106.9 Isoflex 
2 Ag 109 Ag 108.9 Isoflex 
3 Ag Ag 107.9 Fisher Scientific 
4 
Sodium 
borohydride 
NaBH4 37.83 Sigma-Aldrich 
5 Sodium citrate C6H5O7.2H2O.3Na 294.10 Sigma-Aldrich 
6 Nitric acid HNO3 63.01 Fisher Scientific 
7 
Gold (III) 
chloride 
AuCl3 303.33 Sigma- Aldrich 
8 PVP (C6H9O) n 10,000 Sigma-Aldrich 
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Table 2.2 Summary of Characterization of core-shell NPs (Ag@Au@Ag). 
Characterization of core-shell NP synthesis in each step using DLS and UV-Vis. 
 
 DLS UV-Vis 
Sample Size (nm) PDI Wavelength (nm) 
AgNP seed 25.46 0.18 391 
Ag@Au 26.31 0.23 440 
Ag@Au@Ag 28.23 0.12 407 
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Table 2.3 AgNP characterization results. Characterization of PVP-AgNPs in UHPW. 
DLS and TEM size are reported as mean ± standard deviation.  
Parameter Measurement 
DLS size (nm) 33.7 ± 0.7 
Polydispersity index (PDI) 0.18 
Position of maximum UV-Vis absorbance (nm) 390 
TEM size (nm) 4.9 ± 0.3 
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Table 2.4 Mass balance of Ag in the exposure. Ag mass balance in the supernatant and 
cell in AgNP and AgNO3 treatment measured by ICP-MS. Cell data were collected after 
three washes with PBS and shows internalized and strongly bound Ag. Total loss indicates 
loss of Ag during washes or experimental process. Ratio of cell to supernatant in percent 
for Ag uptake.      
  Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.07 0.39 2.40 4.97 
Supernatant 5.17 42.46 212.77 419.88 
Total loss 4.76 57.15 285.62 576.15 
Cell/Sup. (%) 1.35 0.91 1.12 1.18 
AgNO3 
Cell 0.06 0.36 4.56 10.85 
Supernatant 5.49 59.77 120.88 166.46 
Total loss 4.45 39.87 374.56 822.69 
Cell/Sup. (%) 1.09 0.60 3.79 6.52 
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Table 2.5 Mass balance of Ag in the exposure for each person. Ag mass balance (ng) in 
2.5×105 cells (absorbed or cell surface-attached) in AgNP and AgNO3 treatments for each 
of 6-individuals measured by ICP-MS. Data are presented as mean± standard error (n=3). 
 
 Person 1 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.06 0.31 1.76 5.41 
Supernatant 6.23 38.02 153.61 312.95 
Total loss 3.71 61.67 344.62 681.63 
AgNO3 
Cell 0.05 0.32 4.54 8.14 
Supernatant 5.85 57.03 70.21 119.42 
Total loss 4.10 42.65 425.25 872.43 
 
 
 Person 2 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.06 0.34 2.13 4.57 
Supernatant 3.59 33.17 163.68 425.14 
Total loss 6.53 66.49 334.19 570.30 
AgNO3 
Cell 0.05 0.30 4.98 14.44 
Supernatant 6.21 41.29 79.46 142.15 
Total loss 3.74 58.40 415.56 843.42 
 
 
 Person 3 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.07 0.51 2.75 5.96 
Supernatant 4.53 39.64 301.33 457.06 
Total loss 5.40 59.85 195.93 536.97 
AgNO3 
Cell 0.06 0.42 4.97 6.95 
Supernatant 4.78 43.79 83.65 198.16 
Total loss 5.16 55.79 411.38 794.88 
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Table 2.5 Mass balance of Ag. 
 
 Person 4 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.07 0.46 3.58 6.78 
Supernatant 4.55 48.19 206.93 404.74 
Total loss 5.38 51.35 289.49 588.48 
AgNO3 
Cell 0.08 0.51 5.50 11.86 
Supernatant 5.35 70.86 96.16 163.53 
Total loss 4.57 28.64 398.34 824.61 
 
 
 Person 5 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.08 0.38 2.63 4.31 
Supernatant 6.15 45.34 213.65 409.12 
Total loss 3.76 54.28 283.73 586.57 
AgNO3 
Cell 0.08 0.39 4.47 13.54 
Supernatant 5.19 69.46 114.16 158.99 
Total loss 4.73 30.16 381.36 827.47 
 
 
 Person 6 Mass of Ag in exposure (ng) 
  10 100 500 1000 
PVP-AgNP 
Cell 0.07 0.32 1.56 2.79 
Supernatant 5.99 50.41 237.40 510.26 
Total loss 3.94 49.27 261.04 486.95 
AgNO3 
Cell 0.07 0.23 2.91 8.84 
Supernatant 5.57 76.22 120.41 199.83 
Total loss 4.36 23.55 376.68 791.32 
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Figure 2.1 Progressive formation of Ag@Au and Ag@Au@Ag NPs using UV-Vis. 
a) Addition of Au solution to AgNPs to form Ag@Au NPs. As Au is added to the AgNP, 
the Ag peak shift to higher wavelength that shows formation of Au layer. b) Formation 
of Ag@Au@Ag by adding Ag to Ag@Au NPs. Progression of wavelength to lower 
numbers as being coated by Ag. 
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Figure 2.2 AgNP characterization using DLS, UV-Vis, TEM and EDX. 
Characterization of stock PVP-AgNPs using DLS (a), UV-Vis spectra (b), TEM images 
with different magnifications (c and d), and EDX imaging (e). 
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Figure 2.3 STEM images of 1000 µg L-1 PVP-AgNPs and particle size distribution 
obtained by ImageJ. PVP-AgNP in RPMI media (without cells) at (a and b) T= 0, size 
distribution= 29 ± 0.49 nm and (c and d) T= 24 hours, size distribution= 17 ± 11 nm in 
the same condition as cell exposure (5% CO2 and 37°C incubator). 
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Figure 2.4 Behavior of PVP-AgNPs in media during 24-hour exposure. UV-Vis 
spectra of PVP-AgNPs in RPMI media in (a) 1000, (b) 500 and (c) 100 µg L-1 PVP-
AgNP concentration as a function of time. The lowest concentration of exposure (10 µg 
L-1 PVP-AgNP) did not show any signal due to detection limit of UV-Vis.  
a 
b 
c 
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                                                                         PVP-AgNP treatment 
 
 
 
 
 
 
                                                                             AgNO3 treatment 
 
 
 
 
 
Figure 2.5 Dissolved and total Ag concentrations in PVP-AgNPs vs. AgNO3 
during exposure time. Dissolved Ag concentration measurements using centrifugal 
ultrafiltration units (a and c), and total Ag concentration (b and d) in RPMI media at 
T=0 and T=24 hour measured by ICP-MS. All experiments were performed in 
triplicate and are reported as mean ± SE (n=3). 
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Figure 2.6 Dissolved and total concentrations of Ag in AgNO3 in UHPW and media. 
Dissolved Ag concentration were measured using centrifugal ultrafiltration units (a and 
c) and total Ag concentration (b and d) in UHPW and RPMI media at T=0 and T=24 
hours were measured by ICP-MS. Data are reported as mean ± SE (n=3). 
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Figure 2.7 Ag uptake (ng) in 2.5×105 cells.  Results of absorbed or cell surface-attached 
Ag in PVP-AgNP and AgNO3 treatments measured by ICP-MS after 24-hour exposure. 
Data are presented as mean± SE (n=6). * statistically different from 10 µg L-1, ̂  statistically 
different from 100 µg L-1, # statistically different from 500 µg L-1, and ¥ statistically 
different when compared with AgNP treatment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
51 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.8 Ag uptake (ng) in 2.5×105 cells for each person. Results for absorbed or 
cell surface-attached Ag after treatment of PBMCs in 6 individuals. The amount of Ag 
in cells after 3 washes with buffer that was measured by ICP-MS.  
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Figure 2.9 Effects of PVP-AgNP, AgNO3, AgNO3-PVP, and PVP on PBMCs. PBMCs 
were exposed for 24 hours to different concentrations of PVP-AgNP, AgNO3, AgNO3-
PVP, and PVP (0-1000 µg L-1) in RPMI. The effect on cell viability was measured using 
LDH leakage (a). Cell metabolic activity was assessed by MTS assay (b) and results is 
expressed as percentage of reduction values of untreated cells. Data are presented as mean 
± SE as the average of six independent experiments (n=6). * shows statistically significant 
difference from the control (0), and # shows statistically significant difference when 
compared with PVP-AgNP (p < 0.05).   
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Figure 2.10 Cell viability results for each person. Cell viability of PBMCs assessed 
by LDH leakage after 24 hours treatment with representative concentration of PVP-
AgNP, AgNO3, AgNO3-PVP, and PVP. Data represents the means of six replicates ± 
standard error.   
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Figure 2.11 Cell metabolic activity results for each person. Metabolic activity of 
PBMCs measured by MTS assay after 24 hours exposure at the representative 
concentrations for 6 individuals. Data represents the means of six replicates ± standard 
error. 
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Figure 2.12 Pearson correlation between uptake and toxicity of Ag. Correlation 
between uptake and toxicity of Ag in AgNP (a) and AgNO3 (b and c) treatment. There was 
a moderate positive correlation between the two variables (uptake and toxicity) for AgNPs: 
r =0.56, p = 0.01 (a) and AgNO3 excluding person 5: r =0.52, p = 0.04 (b).  No correlation 
was detected in AgNO3 including person 5: r = 0.314, p = 0.2 (c). 
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CHAPTER 3 
 
CAN PVP-COATED IRON OXIDE NANOPARTICLES BE USED TO 
PREVENT WEIGHT GAIN IN A HIGH-FAT DIET MOUSE MODEL 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
57 
3.1 ABSTRACT 
Obesity has become a public health concern for developed countries. More than 
one-third of the adult U.S. population is considered as obese. Current obesity treatments 
are inefficient and may have harmful side effects and consequences. However, 
nanotechnology offers new applications in medicine and drug delivery.  Iron oxide 
nanoparticles (NPs) have the ability to be used as nanocarriers and as contrast agents in 
nanomedicine and magnetic resonance imaging, respectively.  In addition, they have been 
recently used for oil remediation from oil-water mixture.  This study was performed to 
investigate if iron oxide NPs have the potential to remove dietary fat and promote weight 
loss in mice fed a high-fat diet.  Polyvinylpyrrolidone (PVP)-coated iron oxide NPs were 
synthesized and administered orally to mice through food ingestion.  Three different doses 
of PVP-coated iron oxide NPs were administered in the mice diet (≈ 1 mg/kg body weight 
(low-nanoparticle, LNP; n=10), ≈ 5 mg/kg body weight (medium-nanoparticle, MNP; 
n=10) and ≈ 20 mg/kg body weight (high-nanoparticle, HNP; n=10); n=10/group).  Control 
groups consisted of mice consuming a low-fat diet or high-fat diet (n=10) without the 
addition of NPs.  Mouse body weight and food intake was recorded weekly for 16 weeks.  
After 16 weeks of diet, body composition and glucose tolerance test were assessed.  Iron 
accumulation in the liver, kidney, heart, brain, as well as feces was measured using ICP-
MS.  Liver was investigated for lipid accumulation and the presence of inflammatory 
mediators via qRT-PCR.  There was a significant effect of HFD to increase mice body 
weight relative to LFD control.  However, no significant differences among the HFDs in 
mice body weights was detected.  LNP treatment resulted in an increase in fat mass and 
body fat percentage when compared to all other groups.  There was a high fat diet effect to 
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increase fasting blood glucose levels and lipid accumulation in the liver compared to LFD 
control group. Although, no differences in fasting blood glucose levels and lipid 
accumulation among the HFD treated groups was observed.  A dose-dependent increase in 
iron excretion was detected in the feces of the mice treated with nanoparticles.  
Additionally, iron concentration was significantly elevated in the liver of the high 
nanoparticle group relative to the high-fat diet control group.  A significant decrease in 
macrophage marker (EGF-like module-containing mucin-like hormone receptor-like 
1(EMR1)) and macrophage recruitment marker (Monocyte chemoattractant protein 1 
(MCP-1) was found in high nanoparticle treatment when compared with high-fat diet 
group.  This study suggests that consumption of iron oxide nanoparticles in high-fat diet 
food (in the dose up to 20 mg/kg) does not positively effect body weight.  However, it 
might paradoxically modulate macrophages and glucose metabolism.   
  
3.2 INTRODUTION 
Obesity is a universal epidemic.  Due to the consumption of high-fat diets and 
increasing inactive lifestyles, the number of obese individuals has increased greatly across 
the world.  It has been reported that in the U.S. alone more than one third of the adult 
population are obese [179].  Consequently, there has been a concern about health problems 
related to obesity such as diabetes, cancer, metabolic syndrome, and cardiovascular 
diseases and an increase in health care costs [180].  As a result, multiple weight-loss 
strategies have been developed including medication and surgery.  Medications such as 
Orlistat (Xenical) and Qsymia are used as treatment for morbid obesity, but they also can 
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have serious side effects such as increase heart rate , oily rectal leakage [181], liver injury 
[182], insomnia and dizziness [183].  Currently, there is no non-surgical method that can 
both achieve and sustain major weight loss.  Surgical options, such as bariatric surgery and 
liposuction, promote rapid weight loss.  However, this invasive treatment can lead to post-
operative complications including acid reflux, infection, ulcers, bowel obstruction, and 
weight gain [184, 185].   
Nanoparticles (NPs) have been broadly used in different fields such as 
nanomedicine and drug delivery.  They have a unique characteristic that is related to their 
small size which increases their surface to volume ratio providing them novel physical and 
chemical properties. NPs are used widely in personal care, as well as in food and medical 
products. Among the variety of NPs used in biomedical applications, iron oxide NPs have 
attracted significant attention due to their small size and stable magnetic characterization.  
Iron oxide NPs have been used in many applications such as, in vivo NMR technology 
[186], nanocarriers in drug delivery, contrasting agents for magnetic resonance imaging 
(MRI) in clinical diagnosis [187-189] and gene delivery [190].  Recently, PVP-coated Iron 
oxide NPs have been used successfully in oil remediation from oil-water mixtures [1].  
Iron oxide NP toxicity has been examined in vitro [108, 110, 191, 192] (using 
different cell lines) and in vivo [193-195].  An increase in lipid peroxidation in RAW 
macrophages after  2 hours incubation with iron oxide NPs was reported by Stroh et al., 
[186] which was abolished after 24 hours.  They also demonstrated that iron oxide NPs 
does not cause any long term cytotoxicity, even though they are uptaken by RAW cells 
[186]. Moreover, exposure of iron oxide NPs (10-20 µg mL-1) on murine (IL-4-activated 
bone marrow derived) and human (promonocytic THP-1 cells) macrophage models did not 
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cause cell toxicity after 24 hour (up to 100 µg mL-1 exposure) despite the internalization of 
NPs, triggeration of cell activation and alteration in iron metabolism [196].  On the other 
hand, intraperitoneally administration of iron oxide NPs was shown to cause cardiotoxicity 
through oxidatative stress in albino mice [193].  The discrepancy observed in iron oxide 
NP toxicity in the literature could be explained by many factors including different coating 
of NP, size of NPs, routes of exposure, frequency and duration of exposure. 
Our study was designed to investigate the efficiency of iron oxide NPs as an 
effective treatment to reduce fat from high-fat diet mice model.  The specific objectives 
include; 
1) Investigate if our FT synthesized PVP-coated iron oxide NPs are capable to 
remove oil in vitro.  We hypothesized that adding PVP-coated iron oxide NPs 
to synthetic seawater and stomach solution will remove oil efficiently.  To test 
this, we measured and calculated oil removal percentage using a 
spectrofluorometer.   
2) Investigate if there is any difference in food consumption between different 
diets (with and without NPs).  We hypothesized that there is no difference 
between food intake with different diets.  We studied this by measuring food 
intake weekly. 
3) Investigate if iron oxide NPs are capable to induce weight loss in a pre-clinical 
model of obesity.  We hypothesized that mice that consume a high-fat diet rich 
in NPs will loss body weight due to the removal of fat by NPs.  To test this 
hypothesis, we assessed body weight (weekly), body composition (DEXA), 
and weight fat depots at sacrifice.  
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4) Investigate if the iron that is consumed in the food will be excreted in the feces 
or accumulated in tissues (liver, kidney, heart, and brain).  We hypothesized 
that part of the excess iron will be excreted through the feces.  To test this 
hypothesis, we measured iron content in tissues and feces at the end of the 
study. 
5) Investigate if iron oxide NPs are capable to reduce lipid accumulation and 
inflammation in the liver and improve glucose metabolism in a pre-clinical 
model of obesity.  We hypothesized that mice that consume a high-fat diet rich 
in NPs will reduce hepatic lipid and improve glucose metabolism compared 
with high-fat diet.  To test this hypothesis, we assessed hepatic lipid 
accumulation, measured macrophage and inflammatory markers, fasting blood 
glucose, and glucose tolerance in mice fed high-fat diet mixed with NPs. 
To our knowledge, this is the first study which used engineered iron oxide NPs to 
examine fat removal and body weight loss in a mouse model of obesity. 
 
3.3 METHODS 
3.3.1 Synthesis and characterization of iron oxide NPs 
Different synthesis methods have been established to produce iron oxide NPs for 
environmental remediation.  In this study, we used a hydrothermal flow-through synthesis 
(FT) method developed by Kadel et al. [197], to produce cost-effective large-scale 
synthesis of iron oxide NPs.  In brief, 1.5 mmol ferric chloride (FeCl2.4H2O, 98%, Alfa 
Aesar), 4 mmol ferrous chloride (FeCl3.6H2O, >98%, BDH) and 0.3 mmol 
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polyvinylpyrrolidone (PVP) (Mw 10 kDa, Sigma-Aldrich) were dissolved in 6.25 mL 
UHPW at 90°C.  Iron salts and PVP solution was pumped continuously into the reaction 
chamber along with 6.25 mL ammonium hydroxide (NH4OH, 28-30%, BDH) at the same 
flow rate.  The reaction chamber was kept at 90°C inside a water bath.  A black precipitate 
of iron oxide NPs that came out of the chamber was collected.  NPs were washed with 
UHPW using magnetic decantation and re-dispersed in UHPW with sonication.  Iron salts 
were used as precursors and NH4OH was used as a precipitation agent. A schematic of a 
typical FT synthesis is shown in Figure 3.1.   
Z-average hydrodynamic diameter and polydispersity index (PDI) of iron oxide 
NPs were measured using dynamic light scattering (DLS) with a Malvern Zetasizer 
NanoZS (Malvern Instruments, MA, USA).  The mean of at least eight consecutive 
measurements at 25°C after 2 minutes of temperature equilibrium was reported.  PDI is a 
measurement of the quality of NP size distribution.  Zeta potential (colloidal stability) of 
NPS was measured by a Laser Doppler Electrophoresis (Malvern Zetasizer NanoZS, MA, 
USA).  
Total iron concentration was measured using inductively coupled plasma optical emission 
spectrometer (ICP-OES; Varian 710-ES) after washing and removing iron dissolved 
residual.   
3.3.2 Oil removal from water 
Oil separation in seawater was performed using 0.15 g L-1 oil-water mixture. Oil 
concentration was chosen based on previous literature data [198].  Synthetic seawater (30 
ppt) was prepared following the U.S. Environmental Protection Agency (EPA-821-R-02-
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012) protocol [199].  Crude oil, which is representative of the Deepwater Horizon spill 
(reference MC252 surrogate oil; sample ID: A0068H, Aecom Environment), was used for 
oil-water mixture removal experiment.  Oil was mixed with seawater and sonicated for 30 
minutes.  Iron oxide nanoparticles were then added to the oil mixture to obtain suspension 
of 14 mg L-1 of the NPs and sonicated again for 5 minutes.  NPs were separated using a 1 
½ inches cubic neodymium magnet (magnets of Grade N 52, K&J Magnetics INC.) for 1-
hour separation time.  After separation, solution was collected for fluorescence 
spectroscopy measurements.  Emission spectra of samples were measured at excitation 
wavelength of 337 nm and emission range from 350 to 650 nm using a Horiba Jobin Yvon 
Fluorolog-3 spectrofluorometer. These wavelengths were used for detecting polycyclic 
aromatic hydrocarbons (PAHs) and other aromatics [200, 201]. 
3.3.3 Oil separation from stomach solution (in vitro)  
The physiologically extraction test was done using human gastric solution and three 
different oil samples: vegetable oil (Crisco), canola oil (Carnili) and olive oil (Pompian) 
purchased from grocery store.  The gastric solution was prepared following Turner and IP 
protocol [202].  Briefly, 0.5 g of sodium malate, 0.5 g of sodium citrate, 1.25 g of pepsin 
A, 500 µL of acetic acid and 420 µL lactic acid was dissolved in 1 L of UHPW.  The pH 
was adjusted as 2.5 by adding HCL and labeled as gastric solution.  Five mL of gastric 
solution was centrifuged at 3500 rpm for 10 minutes.  Supernatant was collected and stored 
in a 25 mL volumetric flask. UHPW (5 mL) was added to the pellet, centrifuged again 
(3500 rpm for 10 minutes) and supernatant was transferred to a 25 mL flask.  The flask 
solution was then diluted to mark with UHPW.  The following mix was used as stomach 
solution.  A 23 mg from each oil was then added to 10 mL of stomach solution.  PVP-
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coated iron oxide NPs were added for a final suspension of 20 mg L-1 of NPs.  This mixture 
was placed in an incubator/shaker at 37°C for 2 hours.  Then NPs were separated from the 
suspension using a magnet for 30 minutes.  Emission spectra of samples was recorded 
using fluorescence spectroscopy at the same wavelength as the seawater oil removal 
experiment.  The stomach solution and the sample before NP treatment were used as 
control.  
3.3.4 Animal   
Pathogen-free, adult C57BL/6J (wild-type) male mice (n=50) were obtained from 
Jackson Laboratory (Bar Harbor, Maine).  Mice (n=10/group) were housed five per cage 
in a temperature-controlled room at 23-24°C maintained on a 12h light/dark cycle and they 
had ad libitum access to food and water for the duration of the experiment.  All animals 
were treated according to the National Institutes of Health (NIH) Guide for the Humane 
Care and Use of Laboratory Animals and local Institutional Animal Care and Used 
Committee (IACUC) standards.  All experiments were approved by the IACUC of the 
University of South Carolina.   
3.3.5 Diets 
Mice at 4 weeks of age were randomly divided into 5 groups with 10 mice in each 
group.  Mice were assigned to one of five treatment diets as follows: low-fat diet of 10% 
kcal fat (LFD, AIN-76A), high-fat diet of 40% kcal (HFD, SF 12% kcal, USF 28% kcal) 
and three HFD supplemented with: low concentration of PVP-coated iron oxide NP (LNP, 
1 mg kg-1 NPs), medium NP concentration (MNP, 5 mg kg-1 NPs) and high NP 
concentration ( 20mg kg-1 NPs) (BioServ, Frenchtown, NJ).  Diet ingredients was chose 
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based on a typical content of fat in american diet.  The doses of PVP-coated iron oxide NPs 
were chosen based on previous literature [107, 108, 193, 203] in in vivo and in vitro animal 
and human studies [204]).  The doses selected to use in our study were of physiological 
relevance in humans, making them lower than the dose administered in other studies in 
rodents [193, 194, 203]. 
3.3.6 Body weights, food intake and body composition  
Body weight and food intake were recorded on a weekly basis after starting the 
treatments for 16 weeks. Body composition was assessed at the end of treatments (16 
weeks).  For this procedure, mice were briefly anesthesized (using isoflurane) and lean 
mass, fat mass and percent body fat were measured using a Dual- Energy X-ray 
Absorptiometry (DEXA, LUNAR, Madison, WI). 
3.3.7 Glucose Tolerance Test 
A glucose tolerance test (GTT) was performed at week 16 after 5 hours of fasting 
the animals.  After the determination of fasting blood glucose levels, each animal received 
an intraperitoneal glucose average 1.5 g/kg lean body mass of glucose (D-glucose, Sigma, 
St.Louis, MO).  Blood glucose levels were measured after 15, 30, 60 and 120 minutes using 
glucometer (Bayer Contour, Michawaka, IN). 
3.3.8 Tissue collection 
After 16 weeks of dietary treatment, mice were sacrificed under anesthesia (using 
isoflurane) for tissue collection.  Liver, kidney, brain, heart, epididymal, mesentery as well 
as kidney fat pads were collected, weighed and immediately frozen in liquid nitrogen. 
Whole blood was collected from the inferior vena cava using heparinized syringes, and 
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plasma was separated from blood samples using a centrifuge at 4°C at 4000 rpm for 10 
minutes.  Tissue and plasma samples were stored at -80°C for further experiments. 
3.3.9 Iron content measurement in tissues and feces  
Iron content in the selected tissues (kidney, heart, liver, brain) and feces was 
quantified using Finnigan ELEMENT XR double focusing magnetic sector field 
inductively coupled plasma mass spectrometer (SF-ICP-MS).  Tissues were weighed, cut 
and digested using concentrated nitric acid (70% HNO3) followed by heating on a heat 
block using sealed Teflon tubes.  Samples were then diluted to 1% acid and filtered (if 
needed) prior to the measurement of iron concentration with SF-ICP-MS.  Rh was used as 
internal standard and the detection limit was calculated as 0.018 µg/L iron.  The validity of 
the analytical method was checked every five measurements with two quality controls 
(blank and standard).  A serial dilution of iron standard solution (High Purity Standard, 
1000 µg mL-1) was used for calibration curve. 
3.3.10 Hepatic lipid extraction 
Lipids in the liver were isolated using modified Folch extraction method [205] as 
previously described [206, 207].  Liver tissues were weighed and homogenized using 2:1 
chloroform-methanol (v/v) in 5 mL tubes.  After adding NaCl solution and centrifugation, 
a biphasic system was obtained and the clear solution at the bottom of the tube that 
contained most of all the tissue lipids was collected in the glass bottles.  Samples on the 
chloroform layer were dried using nitrogen gas in glass bottles and lipids were assessed 
gravimetrically.  
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3.3.11 Liver gene expression 
Quantification of liver gene expression for selected macrophage markers (EMR1) 
and inflammatory mediators (tumor necrosis factor (TNF-α), monocyte chemotactic 
protein (MCP-1), and interleukin (IL)-6) were performed.  Liver samples were 
homogenized and total RNA was extracted using Trizol reagent (Invitrogen, Calsbad, CA). 
The extracted RNA was dissolved in diethyl pyrocarbonate (DEPC)-treated water and 
quantified spectrophotometrically at 260 nm wavelength.  RNA was used to synthesize 
cDNA and quantified RT-PCR analysis was done using Taqman Gene Expression assays.  
Potential reference genes hydroxymethylbilane synthase (HMBS) and H2A histone family 
member V (H2AFV) were used as internal control for liver tissue. 
3.3.12 Measurement of vitamin A and E in plasma 
Plasma samples were used to quantify lipid soluble vitamins (A and E) using LC 
MS/MS. * Still waiting for results. 
3.3.13 Statistical analysis 
The data were analyzed using Prism 7 (GraphPad Software, USA).  Comparisons 
were tested with one-way analysis of variance (ANOVA) followed by a Student-Newman-
Keuls post hoc analysis.  Differences were considered statistically significant when p < 
0.05 in all experiments.  Results are expressed as the mean ± standard error. 
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3.4 RESULTS 
3.4.1 NP synthesis and characterization 
PVP-coated iron oxide NPs were synthesized using a continuous hydrothermal FT 
following Kadel et al.’s protocol.  The mean hydrodynamic diameter of NPs was measured 
using DLS in water and was recorded as 116 ± 4.9 nm with an average PDI of 0.26 (Figure 
3.2).  Zeta-potential was measured as 10.6 ± 0.8 mV from 10 repeated measurements. Other 
characterization data are reported in the previous study [197].  
3.4.2 Oil separation from seawater using PVP-coated iron oxide NPs 
To check the efficiency of NPs and compare that with previous studies, oil removal 
property of PVP-coated iron oxide NPs was analyzed using synthetic seawater.  Figure 3.3 
shows the fluorescence spectra for the seawater with and without oil, before and after NP 
treatment. The concentration of NP that was used for oil separation was 14 mg L-1.  A 
significant decrease in fluorescence spectra for seawater after NP treatment was observed.  
Results showed the percentage of oil removal as 94% from seawater.  
3.4.3 Oil separation from stomach fluid using iron oxide NPs 
The oil removal in the stomach solution was examined using canola, olive and 
vegetable oil.  Figure 3.4 shows a significant reduction in fluorescence spectra for all three 
oils that were used.  According to these results, the percentage of oil removal was 
calculated as 85%, 84% and 89% in canola, vegetable and olive oil, respectively.  
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3.4.4 Body weight and fat pad weights 
Body weight and fat pad weights are presented in Figure 3.5.  Mice were fed LFD, 
HFD, or HFD supplemented with different concentrations of PVP-coated iron oxide NPs 
for 16 weeks.  The mice consuming HFD and LNP had significantly elevated body weights 
compared with LFD (control diet) starting at week 2 (p < 0.05).  This effect began later for 
HNP and MNP mice (week 4 and 5 compared with LFD, respectively) (p < 0.05).  No 
significant difference in body weight was observed between HFD and HFD supplemented 
with different concentrations of PVP-coated iron oxide NPs througout the study. 
Measuring individual food intake for each mouse was not possible, because they 
were housed five mice per cage.  However, no significant differences was observed 
between all diets in weekly food intake during the study.  
For all fat-pad depots, the HFD-fed mice showed an increase in fat mass compared 
with LFD-fed mice (control) (p < 0.05) (Figure 3.5c).  Although, there was no significant 
difference between HFD and HFD supplemented with NPs in epididymal fat weight, the 
LNP treated group showed a greater mesentery and peri-renal fat weight than HFD, MNP 
and HNP (p < 0.05).   
3.4.5 Body composition  
Body composition analysis was performed after 16 weeks of diet (Figure 3.5d).  In 
the HFD and HFD supplemented with NPs-fed mice, fat mass, and fat percentage had 
increased significantly when compared to control group (LFD) (p < 0.05).  LNP group had 
enhanced fat mass and fat percentage compare to HFD, MNP and HNP mice (p < 0.05).  
There were no significant differences in body fat and fat percentages between HFD, MNP, 
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and HNP-fed mice.  No differences in lean mass was observed between groups at the end 
of the study.  
3.4.6 Effect of PVP-coated iron oxide NP diet on glucose metabolism  
Glucose tolerance test (GTT) was performed on mice after 16 weeks of diet.  HFD 
and HFDs supplemented with iron oxide NPs-fed mice showed elevated fasting blood 
glucose (Figure 3.6a) and GTT AUC (area under the curve) (Figure 3.6c) when compared 
to control group (LFD) (p < 0.05).  No significant difference was observed in the fasting 
blood glucose between HFD and HFD with NPs.  LNP and MNP treatments also displayed 
elevated GTT AUC compared with HFD, demonstrating a dysfunctional glucose 
metabolism (p < 0.05).  There was no significant difference in GTT AUC between HFD 
and HNP-fed diet treatment.  
3.4.7 Iron content in feces and tissues  
As expected, we observed similar iron content in the feces of LFD and HFD treated 
groups.  A significant dose dependent increase in iron content was observed in the feces 
(Figure 3.7a) of PVP-coated iron oxide NP treated animals when compare to LFD and HFD 
groups (p < 0.05).  Then, we investigated if PVP-coated iron oxide NPs accumulated in the 
brain, heart, kidney, and liver.  For this we selected only the HNP group as they should 
have the highest amount of iron.  HFD group was used as a control to compare iron 
accumulation in tissues.  No changes in iron content was observed in the brain, heart, and 
kidney between HNP and HFD treated mice.  However, we observed a significant increase 
in the iron content in the liver of HNP treated mice when compared to HFD group (Figure 
3.7b) (p < 0.05).  
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3.4.8 Hepatic lipid accumulation and inflammatory markers 
To determine if PVP-coated iron NPs were able to remove lipid content and 
decrease inflammation in the liver, we measured liver mass, hepatic lipid accumulation, 
and the gene expression of macrophages (EMR1), a chemokine (MCP-1), and cytokines 
(TNF-α and IL-6) markers.  HFD and HFDs supplemented with NPs treatments displayed 
a significant increase in the liver weight (hepatomegaly) (Figure 3.8a) (p < 0.05) and 
accumulation of lipids in the liver (hepatic steatosis) when compared to LFD treatment (p 
< 0.05).  Mice treated with different concentrations of NPs did not show any significant 
difference between liver weight and hepatic lipid accumulation when compared to HFD 
treatment (Figure 3.8b).  
Inflammatory markers was assessed via RT-PCR in LFD, HFD, and HNP treated 
mice. HFD treated mice displayed an increase in EMR1, MCP-1, and TNF-α  expression 
when compared to LFD treatment (Figure 3.8c and d, p < 0.05).  HNP treatment 
significantly decreased gene expression of EMR1and MCP-1 when compared to HFD 
group (Figure 3.8c and d, p < 0.05).  Despite a reduction in EMR1 in the liver of HNP 
treated mice, no effect was detected in the gene expression of TNF-α and IL-6 compared 
with HFD group (Figure 3.8e).  No significant difference was observed in IL-6 gene 
expression across examined groups (Figure 3.8f).    
 
3.5 DISCUSSION 
Obesity is one of the current health challenges in the America, mainly because it is 
associated with inflammatory metabolic disorders (such as insulin resistance, steatosis 
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hepatis and type 2 diabetes) [208].  Current treatments (including non-surgical and surgical 
therapies) have their own limitations and side effects [182-185].  Nanomaterials have been 
considered as possible medicines for gene/drug delivery and imaging [209].  Among 
nanomaterials, iron oxide NPs have attracted a great deal of attention, especially in imaging 
and nanomedicine because of their small size and magnetic properties [210].  Recently, 
PVP-coated iron oxide NPs have been used for oil removal [1] and results indicated 
excellent removal efficiencies under laboratory conditions from aqueous solutions [1].  
However, it is not known if in complex scenarios such as, in vivo systems, whether PVP-
coated iron oxide NPs are capable to remove excess oil/fat from animals.  In this study, we 
tested for the first time the ability of PVP-coated iron oxide NPs (synthesized in house) to 
remove dietary fat in in vivo model using mice fed with HFD.  
PVP-coated iron oxide NPs were synthesized using a hydrothermal FT [197]. 
According to DLS data and distribution profile, it is possible to conclude that NPs 
presented a monodisperse NPs (mean size of 116 ± 4.9 nm, PDI: 0.2).  The narrow DLS 
peak suggests a homogenous system with size close to the mean.  Zeta-potential, which 
was measured as 10.6 ± 0.8 mV, confirmed steric stabilization of NPs by PVP and an 
absence of a significant charge on the NPs [149].  The synthesis procedure of iron oxide 
NPs is influenced by many factors such as time, solution pH and temperature; therefore, 
synthesis should be controlled carefully to obtain consistent and reproducible NPs [211].   
The magnetic properties of iron oxide NPs allow separation of NPs from water and 
oil mixture using a magnet.  Hydrophobic PVP, which is a non-toxic polymer [150] and 
coating agent, is capable of absorbing oil through interaction between hydrophobic fraction 
of PVP and hydrocarbons [197].  It is suggested that hydrophobic moieties of PVP coating 
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absorbs oil from the solution onto the NP surface and then the magnetic property of iron 
oxide NP easily separates NPs associated with oil from the solution [197].  Previously it 
was shown that PVP-coated iron oxide NPs are capable of removing almost all aromatic 
and a majority of the aliphatic oil components [212].  In this study, we tested the ability of 
our synthesized PVP-coated iron oxide NPs to remove oil from synthetic seawater; oil 
removal percentage was calculated as 94%, which is acceptably close to the number which 
Kadel et al., and Mirshahghassemi et al., achieved (got more than 98% of oil removal in 
the same media) [1, 197].  In vitro experiments that were performed using stomach solution 
and three different oils resulted in 85%, 84% and 89% oil removal for canola, vegetable 
and olive oil, respectively, which shows an acceptable percentage of oil removal.  The 
reduction in the efficiency for the oil removal may be because of the synthesis method (FT 
synthesis) that was used to increase the efficiency and decrease the cost of synthesis.  This 
problem could be solved by adding larger masses of iron oxide NPs and/or increasing the 
separation time.    
To obtain comprehensive information on the efficiency of NPs on fat removal in 
vivo, we administered different concentrations of PVP-coated iron oxide NPs (1, 5 and 20 
mg/kg mouse body weight) in the food.  Additionally, we used a LFD and HFD without 
NPs as control groups.  After 16 weeks of diet-treatments we observed no significant 
differences in body weight of mice treated with NPs when compared between themselves 
and to the HFD control group.  LNP treatment showed higher total fat pad, fat mass and 
body fat percentage compared with other diets.  However, no changes were observed in 
their body weight, lean mass and liver weight.  This leads us to suggest that perhaps the 
low concentration of PVP-coated iron oxide NPs is accumulating in the fat tissue and might 
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be contributing to the increase of fat mass in these mice.  We believe we did not see increase 
in fat mass in MNP and HNP mice because NPs at these concentrations might have some 
aggregation.  We could visibly observe NPs aggregation in the food of medium and high 
NP concentration (Figure 3.9).  If NPs are aggregated even before mice consumption, this 
could affect the ability of NPs to bind to the oil/fat and decrease NP efficiency.  A more 
specific oil binding phase on the particles, rather than only PVP might help with 
aggregation and the oil removal property of iron oxide NPs.    
Obesity is associated with an increase in the prevalence of type 2 diabetes, 
hypertension and impaired glucose metabolism.  To assess if a diet supplemented with 
PVP-coated iron oxide NPs influence glucose metabolism, we measured fasting blood 
glucose at the end of 16 weeks.  It has previously been shown that HFD feeding elevates 
blood glucose levels and cause insulin resistance in rodents [213]. Our results showed that 
NP treatment did not mitigate impaired glucose metabolism.  Surprisingly, LNP and MNP 
treatment showed a greater degree of impaired in glucose metabolism (GTT AUC) than 
HFD treated mice.  Once again, this effect on HNP mice might have been hindered due to 
increases in aggregation in the diet.   
Iron was measured in the feces and selected tissues (brain, heart, kidney and liver) 
to investigate the fate of iron in the body.  In the feces, a dose dependent increase in the 
iron excretion was found as the concentration of iron in the diet increased.  Considering 
the iron background in the LFD and HFD (that was added to the food as a supplement by 
the food company), we can conclude that most of the iron that is excreted through feces is 
from NP consumption (48%, 69% and 81% for LNP, MNP and HNP, respectively).  In the 
iron measurements from selected tissues, no significant difference was observed in brain, 
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heart, kidney.  However, liver from HNP treated mice showed higher accumulation of iron 
than the liver of HFD mice (LNP and MNP were not measured) which suggests iron is 
taken up by the liver cells.  Our result is consistent with previous studies who found more 
NPs in the liver after treatment with iron oxide NPs [214-216].  A biodistribution study of 
DMSA-iron oxide NPs in vivo showed that NPs are transformed to organs that are 
responsible for iron regulation (liver and spleen) [217].  The ability of liver to uptake more 
NPs is referred to as an active mononuclear phagocyte system (specially Kupffer cells) 
which works as an immune network to remove alien material [218].  In addition, due to the 
large surface area of NPs, the interaction between macrophages and NPs could be 
facilitated, leading to fast recognition and clearance by macrophages.  This was shown by 
Stroh et al., who reported a massive uptake of iron NPs by RAW macrophages without any 
effect on cell viability [186].  However, more studies are needed to better understand the 
interaction between PVP-coated iron oxide NP treatment and glucose metabolism.  A 
limitation of the study is that we were not able to calculate iron mass balance due to the 
study design. 
Obesity is considered as a low-grade inflammatory disease that is characterized by 
infiltration of macrophages in the tissues, which leads to inflammatory mediators secretion 
(such as TNF-α and IL-6) [219, 220].  Interestingly, we found a significant decrease in 
gene expression of macrophage (EMR1) and macrophage chemokine (MCP-1) markers in 
the liver tissue of HNP treatment relative to HFD (almost as low as LFD group).  Others 
have reported an increase in monocyte recruitment in bronchoalveolar macrophages 
exposed to DMSA-coated iron oxide NPs [221].  IL-6 is known as a factor that mediates 
inflammatory responses in obesity and its elevated levels in plasma was reported before 
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[222].  However, we did not find any increase in IL-6 in the liver which is consistent with 
previous studies [220, 223].  TNF-α as an inflammatory factor exhibited an increase in the 
HFD-fed mice, as was shown previously [220].  However, we could not detect any 
significant difference in TNF-α between HFD and HNP groups.  The liver is recognized as 
the main organ of iron deposition and cell injury [224].  TNF-α has potent proinflammatory 
and cytotoxic effects and is the major mediator secreted form Kupffer cells that are hepatic 
resident macrophages.  Continued induction of TNF-α expression is an important feature 
of chronic inflammatory liver disease [225] and the results of She et al., showed iron up-
regulate expression of TNF-α in Kupffer cells [226].  The inability to detect a decrease in 
TNF-α gene expression in the liver (despite the decrease in the macrophage gene 
expression) may be due to the ability of other cells (such as hepatocytes) to compensate for 
the macrophages and secrete more TNF-α.  However, a more comprehensive analysis is 
needed to determine the reason for the significant decrease in hepatic macrophages and 
stable gene expression of IL-6 resulting from PVP-coated iron oxide NP treatment.  One 
limitation of this study was the gene expression measurement, which was performed only 
by qRT-PCR.    
Although our in-vitro tests showed promising fat removal results using PVP-coated 
iron oxide NPs from stomach solution, our data in a more complex model in-vivo was not 
able to mimic this effect.  Oral exposure of PVP-coated iron oxide NPs mixed in a high-
fat diet at concentrations up to 20 mg/kg body weight did not show any effect on body 
weight loss and/or fat accumulation in the liver.  In fact, low and medium concentration of 
NPs might aggravate glucose metabolism.  The discrepancy between in-vivo and in-vitro 
model could be due to NP aggregation in HFD, ingestion and excretion process, and 
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interaction of PVP-coated iron NPs with other cells.  Therefore, further studies, such as, 
optimizing routs, concentration and surface modifications of NPs are necessary to 
corroborate if iron oxide NPs are capable to remove oil/fat in in-vivo systems. 
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Figure 3.1 Schematic diagram of flow-through synthesis of PVP-coated iron oxide 
NPs (figure not on scale).  Adopted from Kadel et al. 2018. 
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Figure 3.2 Size characterization of iron oxide NP. DLS size distribution plot indicated a 
mean size of 116 ± 4.9 nm. 
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Figure 3.3 Fluorescence spectra for the seawater before and after oil removal. Oil 
removal efficiency was calculated as 94% from synthetic seawater.  
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Figure 3.4 Fluorescence spectra of oil removal from stomach fluid using iron oxide 
NPs. Oil was removed from stomach solution after 1-hour separation time using a magnet. 
Percent oil removal was calculated as: canola oil: 85%, vegetable oil: 84% and olive oil: 
89%. 
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Figure 3.5 Body morphology and food intake after 16 weeks of treatment. Body 
weight, food intake and fat pad weights after 16 weeks of treatment (low-fat diet (LFD), 
high-fat diet (HFD), low nanoparticle (LNP), medium nanoparticle (MNP) and high 
nanoparticle. Mice were fed for 16 weeks. a) body weight; b) food intake; c) fat pad weight; 
and d) body composition measured by dual-energy X-ray absorptiometry (DEXA). Data 
are presented as means ± SE; n =10 mice per group. Bar graphs not sharing a common 
letter are significantly different (p < 0.05). 
 
a 
b 
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Figure 3.6 Metabolic data after 16 weeks of treatment. Mice were administered with 
(low-fat diet (LFD), high-fat diet (HFD), low nanoparticle (LNP), medium nanoparticle 
(MNP) and high nanoparticle for 16 weeks. a) fasting blood glucose levels (5h); b) glucose 
tolerance test (GTT); and c) corresponding area under the curve (AUC). Values are 
presented as mean ± SE; n =10 mice per group. Bar graphs not sharing a common letter 
differ significantly from each other (p < 0.05). 
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Figure 3.7 Iron measurement in feces and tissues using ICP-MS after 16 weeks of 
dietary treatment. Iron measurement after 16 weeks of treatment ((low-fat diet (LFD), 
high-fat diet (HFD), low nanoparticle (LNP), medium nanoparticle (MNP) and high 
nanoparticle (HNP), in a) feces and b) brain, heart, kidney and liver. Values are presented 
as mean ± SE; n= 4 mice per group. Bar graphs not sharing a common letter differ 
significantly (p < 0.05). 
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Figure 3.8 Hepatic lipid accumulation and inflammatory mediators. a) liver weight 
after euthanasia, low-fat diet (LFD), high-fat diet (HFD), low nanoparticle (LNP), medium 
nanoparticle (MNP) and high nanoparticle (HNP); b) hepatic lipid accumulation; c) hepatic 
gene expression of EMR1; gene expression of hepatic inflammatory mediators: MCP-1 
(monocyte chemoattractant protein-1, TNF-α (tumor necrosis factor-α) and IL-6 
(Interleukin-6) normalized to the HMBS and H2AFV. Data are presented as mean ± SE; n 
= 10 mice per group. Bar graphs not sharing a common letter are significantly different (p 
< 0.05). 
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Figure 3.9 Mice diet. Mice diet modified as: Fat (40% kcal); SF (12% kcal), USF (28% 
kcal), a) high nanoparticle; b) medium nanoparticles; c) low nanoparticles. 
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CHAPTER 4 
 
OVERALL CONCLUSION 
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The purpose of this dissertation was to investigate the effect and application of Ag 
and iron oxide NPs in mammals (using human blood cells and mice model, respectively).  
This aim was achieved by:  
A) Investigating the uptake and cytotoxicity of AgNP and AgNO3 (as control) to human 
PBMCs.   
The overall conclusions are summarized as below: 
1) Uptake and toxicity of AgNPs and AgNO3 were investigated using well-
characterized PVP-coated AgNPs on human PBMCs.  In summary, our study 
showed that PVP-AgNPs are more stable in the RPMI media than Ag ions that 
could be associated with a decrease in the bioavailability of Ag ions to the cells.  
2) We determined that a combination of AgNP transformations is happening in the 
complex cell culture media that influence NP uptake and cytotoxicity. 
3) In terms of overall observed toxicity, AgNPs and AgNO3 showed the same 
cytotoxicity. Although, in terms of toxicity normalized to the amount of Ag that is 
taken up by the cells, particles seem to be more toxic to PBMCs than ions.  
4) This data underscores the importance of sufficient characterization of NPs in proper 
exposure media for duration of exposure, to have a better understanding of NP 
behavior and interaction in biological systems for evaluating risk assessment in 
human exposure.  
B) Investigating the efficiency of iron oxide NPs to remove fat from a HFD-fed-mouse 
model. 
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 The overall conclusions are summarized as below: 
5) Using PVP-coated iron oxide NPs we could remove canola, vegetable, and olive 
oil from stomach solution with high removal efficiency percentages (85%, 84% and 
89%, respectively).   
6) Despite the promising results in vitro, orally administration of PVP-coated iron 
oxide NPs through food at concentrations up to 20 mg/kg did not show any effect 
on body weight loss and lipid content in the liver of high fat diet-fed mice. 
7) Some degree of glucose metabolism impairment was detected in NP treatment 
groups.  However, inflammatory markers in the liver (TNF-α and IL-6) did not 
show any elevation.  Further studies are needed to better understand the role of 
PVP-coated iron oxide NPs in metabolic processes.   
8) As our in-vitro data showed reassuring results, we are optimistic that with some 
modifications in the experimental design, such as doses of NPs, surface 
modification of NPs, and a more reliable and applicable route of exposure, iron 
oxide NPs can be used to investigate if iron oxide NPs can be used as an anti-obesity 
treatment.   
In this study, we investigated the impact of nanotechnology and nanomaterials in 
mammals.  Our research results can be used for further advancement research and to add 
information for potential rules and regulations for the utilization and application of 
nanoparticles in commercial products.  
While the number of publications in the nanotechnology and nanotoxicology field 
is increasing each year, no standardize protocol is published for systematic analyzing of 
90 
toxicology of NMs (Nat Nano, 2012).  Factors like cell viability assays, NPs 
characterization, culture media conditions and toxicology assays that are not standardized 
could make differences in the results and in the results interpretation.  
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